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CHAPTER 1 
 
General introduction and outline  
of this thesis 
 Pompe disease, also referred to as glycogen storage disease type II or acid 
maltase deficiency, is an autosomal recessive, progressive, debilitating disease. 
This neuromuscular disorder is characterized by progressive muscle weakness. As 
part of the disease process, the muscles of the trunk and pelvic girdle start to 
become affected first and gradually the disease process spreads from the 
proximal to the distal muscles of the legs and arms. The muscles of the hands and 
feet are relatively spared until late in the disease process. The respiratory 
muscles, which include the diaphragm, are involved as well. The emerging 
mobility and respiratory problems  have a great impact on daily functioning and 
quality of life of patients with Pompe disease.  
Pompe disease was the first neuromuscular disorder for which disease specific 
treatment became available. The introduction of enzyme replacement therapy 
(ERT) with recombinant human alfa-glucosidase (the enzyme deficient in Pompe 
disease) has improved the prospects of patients. With the growing attention for 
Pompe disease the role of physiotherapy also became more prominent. 
Physiotherapy not only plays an important role in identifying and quantifying 
motor and functional limitations and recommendation of appropriate adjuvant 
physiotherapeutic interventions, but in the monitoring of disease progression and 
evaluation of the effect of enzyme replacement therapy and physiotherapeutic 
intervention as well.  
This introductory chapter provides background information on Pompe disease 
with regard to its pathology and clinical manifestations, and describes the role of 
physiotherapy in the treatment of patients with Pompe disease.  
  
 
 
 
POMPE DISEASE 
Pompe disease derives its name from the Dutch pathologist JC Pompe, who 
described the disease in 1932. He reported a case of a 7 month-old girl who died 
of cardiomyopathy [1]. The disease was identified as a glycogen storage disorder, 
later named as glycogen storage disease type II, in which glycogen had 
accumulated within vacuoles of all examined tissues, including skeletal muscles. 
Glycogen is an important source of energy primarily in the cells of the liver and 
skeletal muscle. In the degradation and synthesis of glycogen many enzymes are 
involved. Deficiencies of these enzymes can lead to abnormal glycogen 
metabolism, and as a consequence a glycogen storage disorder may develop. In 
1963 Hers identified acid α-glucosidase (GAA), the enzyme which is responsible 
for the breakdown of glycogen in the lysosome, and reported its absence in tissue 
samples of five patients suffering from Pompe disease [2]. Pompe disease is a 
glycogen storage disorder and also belongs to a group of diseases known as the 
lysosomal storage disorders.  
PATHOGENESIS AND PATHOPHYSIOLOGY  
In general, lysosomal storage disorders (LSDs) are diseases in which the lysosomal 
function is impaired due to a deficiency of a lysosomal enzyme leading to 
accumulation of the macromolecules it should degrade. In Pompe disease the 
lysosomal dysfunction is provoked by the absence or deficiency of the enzyme 
acid α-glucosidase. Pathogenic sequence variations in the gene coding for GAA, 
which is located on chromosome 17, can result in GAA protein not being produced 
at all, abnormal processing of GAA or reduced amounts or normal GAA. The c.-32-
13T>G splice site variation is the most common sequence variation among 
Caucasian children (60%) and adults (>80-90%) with Pompe disease. The c.-32-
 
 
 
13T>G leads to variable splicing with production of 10-20% normal GAA protein 
and residual GAA activity and anon-classic or late onset presentation. Most 
patients who took part in the studies described in this thesis carry the c.-32-13T>G 
on one allele. Pompe disease inherits in an autosomal way; both GAA alleles need 
to carry a pathogenic sequence variation for the disease to manifest.  
Glycogen metabolism is regulated bij various enzymes. GAA is needed for the 
breakdown of glycogen that has entered the lysosome through autophagy. 
Normally, glycogen gets degraded to glucose in the lysosome by GAA . Deficiency 
of this enzyme leads to continuous accumulation of lysosomal glycogen, resulting 
in an increase of lysosomes in size and number, loss of their function and rupture, 
followed by cellular damage. This process can be found in virtually all cells of the 
body, but the effects are most notable in muscle cells [2, 3].  
The pathophysiology of muscle damage and the reduction in mechanical 
performance of muscles is not fully understood in Pompe disease. Accumulation 
of lysosomal glycogen leading to the aforementioned cascade may cause 
mechanical loss of contractility resulting in muscle weakness [4, 5]. A second 
hypothesis is that autolytic enzymes, released from ruptured lysosomes, are 
involved in muscle damage and wasting [6]. The autophagic buildup containing 
cellular debris representing a huge non-contractile inclusion in the diseased 
muscle fibers may also contribute to the muscle weakness [7]. Further, it has been 
shown that satellite cells, which are essential for muscle regeneration are unable 
to prevent progressive muscle wasting due to insufficient satellite cell activation 
[8].   
  
 
 
 
PRESENTATION, CLINICAL SPECTRUM AND DIAGNOSIS 
Pompe disease is a rare disease. In the Netherlands, its overall incidence is 1 in 
40,000 births [9]. The disease can manifest at any age and with varying symptoms 
resulting in a continuous spectrum of disease phenotypes [10]. This spectrum 
ranging from a severe, rapidly progressive classic-infantile form to more slowly 
progressing phenotypes that can manifest from early childhood to late adulthood 
[11, 12]. There is an association between these phenotypes and α-glucosidase 
activity, but secondary genetic and environmental factors may play a role as well. 
[13, 14].  
The classic-infantile form of Pompe disease presents shortly after birth, at a 
median age of 1.6 months (range 0-6.8) [12]. These infants usually have hardly 
any GAA activity. The disease is rapidly progressive and characterized by 
hypertrophic cardiomyopathy and extreme hypotonia. Patients are unable to 
achieve motor milestone and patients die from cardiorespiratory failure in the 
first year of life in the absence of treatment [10, 12, 15]. 
Onset of symptoms in patients with non-classic disease may range from the first 
to the sixth decade of life. These patients have some residual acid α-glucosidase 
activity. Patients have a gradual developing proximal myopathy, which typically 
fits a pattern of limb-girdle diseases. It causes both mobility and respiratory 
problems and eventually leads to wheelchair and/or ventilator dependency, with 
respiratory failure as the main cause of death. This thesis will focus on adult 
patients with non-classic Pompe disease.  
 
 
 
 
Figure 1 | The clinical spectrum of Pompe disease 
This figure was adapted from Güngor and Reuser. How to describe the clinical spectrum in 
Pompe disease? Am J Med Genet A 2013; 161A(2):399-400, by permission of John Wiley 
and Sons. 
 
Diagnosing Pompe disease is often difficult due to the heterogeneous clinical 
presentation, the overlap of symptoms with other neuromuscular diseases and 
the relative rarity of the disease. The diagnosis of Pompe disease can be 
established by demonstrating deficiency of acid-α-glucosidase activity in 
leukocytes, fibroblasts or skeletal muscle and/or genetically by mutation analysis 
[16]. 
 
THE HEALTH CONDITION OF PATIENTS WITH POMPE DISEASE ACCORDING TO 
THE ICF MODEL: IMPAIRMENTS, LIMITATIONS IN ACTIVITY  AND RESTRICTIONS 
IN PARTICIPATION 
The International Classification of Functioning, Disability and Health (ICF) of the 
World Health Organization (WHO) [17] provides a framework to describe a health 
condition of a patient, which incorporates the biological, individual and social 
 
 
 
elements that affect health. In this model, as illustrated in Figure 2, a health 
condition or disease can be described multidimensional by the problems at the 
body or organ level, those with execution of tasks (activity), and by restrictions in 
participation in daily life. All components of this model are important and may 
interact with another. 
 
Figure 2|  ICF model  
This figure was adapted from the World Health Organization, 2001 
  
 
 
 
BODY FUNCTIONS & STRUCTURE LEVEL  
At the body and organ level, Pompe disease is characterized by a slowly 
progressive symmetrical myopathy, starting from the trunk with early 
involvement of paravertebral and abdominal muscles, and gradually moving to 
the extremities [18-21]. Data from the international registry showed that proximal 
muscle weakness was observed in the lower extremities in 89% of adult patients 
and in the upper extremities in 73%; weakness of the trunk was observed in 65% 
[13]. Figure 3 gives a schematic overview of the muscles that are affected in adult 
patients with Pompe disease, and the severity of the weakness [11].  
Finally, selective muscle weakness in the extremities leads to coordination 
problems, axial muscle weakness to impaired core stability and posture problems 
(i.e. scoliosis and increased lumbar lordosis) and scapula alata, which is reported 
in one third of the adult population [11, 22]. Less familiar features of Pompe 
disease are bulbar weakness, ptosis and incontinence. Incontinence has been 
associated with glycogen accumulation in both smooth muscle fibers of the 
bladder and intestine [23, 24] and skeletal muscles of the pelvic floor [18, 21]. 
Also the respiratory muscles and diaphragm are affected in Pompe disease, with 
the diaphragm being by far the most impaired muscle [25, 26]. This results in 
reduced pulmonary function. A cross-sectional study in Dutch adult patients 
showed that 79% of the patients had some degree of pulmonary dysfunction [27], 
leading to dyspnoea with exertion or when supine and impaired cough. 
Altogether, the skeletal muscle weakness and respiratory problems can lead to 
decreased endurance.  
 
 
 
 
Figure 3| Distribution (A) and severity (B) of muscle weakness in adults with Pompe 
disease.  
This figure was adapted from van der Beek et al. Clinical features and predictors for 
disease natural progression in adults with Pompe disease: a nationwide prospective 
observational study. Orphanet J Rare Dis 2012;7:88, by permission of BioMed Central. 
 
Finally, pain and fatigue are reported by adult patients with Pompe disease. 
Nearly one in two Dutch patients reported having experienced pain in the 
previous 24 hours [28]. This was most frequently reported in the shoulder region, 
back and the upper legs, and was described as exhausting (70%) or pulling/tearing 
(57%). Both postural problems and muscle pain might be underlying mechanisms 
[29]. Fatigue is highly prevalent among both mildly and severely affected adult 
patients with Pompe disease. [30, 31]. It has been reported that 79% of the 
patients receiving ERT were fatigued and 55% severely fatigued. 
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ACTIVITY LEVEL  
Due to muscle weakness of the trunk and limb-girdle, patients experience gradual 
difficulty with motor function, noted initially in problems with walking and 
running [22]. It can also limit performance of activities of elevation against gravity 
such as climbing stairs, getting up out of a chair, and lifting the arms overhead [22, 
32, 33]. The majority of patients with Pompe disease (8 out of 10) experience 
problems with walking [22, 33], varying from imbalance to compensatory 
movement patterns such as Duchenne or Trendelenburg signs or a swayback 
posture. Eventually, these problems will lead to dependency of walking aids and, 
ultimately, patients will lose the ability to walk and become wheelchair 
dependent.  
PARTICIPATION LEVEL  
Pompe disease has a large impact on the level of participation of patients in life 
[34]. The loss of the ability to walk hampers daily activities such as domestic tasks, 
work and outdoor leisure activities. Reduced respiratory functioning, pain, fatigue 
and incontinence will further add to this.  
Quality of life has been shown to be significantly affected in adult patients [22, 
34]. The physical health status appears to be less than that of people in the 
general population [16, 35], where wheelchair use is associated with lower 
physical and social functioning scores, and the use of artificial ventilation with 
lower physical scores [35]. Paradoxically, the mental-health status of patients with 
Pompe disease was found not be reduced. Is might be due to better coping 
strategies patients developed over time. Personal factors influence how a disease 
and/ or disability is experienced.  
 
 
 
Also environmental factors play an important role in people’s functioning. These 
factors range from physical factors (such as climate, terrain or building design) to 
social factors (such as attitudes, institutions, and laws)[17]. The aforementioned 
impairments, limitations in activity, and restrictions in participation that often 
accompany Pompe's disease can be displayed in the ICF model as follows 
(see figure 4).  
 Figure 4 | ICF-model: Overview of health problems that often accompany Pompe's disease and the factors that can influence these 
problems  
CURRENT THERAPEUTIC APPROACH 
Since 2006, enzyme replacement therapy (ERT) with recombinant human acid α-
glucosidase has been approved for the treatment of Pompe disease. Several 
studies in children and adults have shown effects of ERT on walking distance, 
pulmonary function, muscle strength and muscle function and on survival [36-39]. 
However, the results also suggest that there is a large variation in the effects of 
treatment in these patients. Improvement of the remaining functional 
impairments of these patients is still desired. Physiotherapy to advance physical 
functioning of patients might be beneficial in this.  
PHYSIOTHERAPY IN POMPE DISEASE 
Physiotherapy (PT) tries to influence impairments of the musculoskeletal system 
and promotes mobility and function by using mechanical force and movements, 
manual therapy, exercise therapy, and electrotherapy. It encompasses both 
examination, diagnosis, prognosis, monitoring and physical intervention. It has a 
clear role in treating symptoms of acute diseases and its role in treating symptoms 
of chronic diseases is also well recognized. In patients with neuromuscular 
disorders one of the primary questions is whether exercise training may be 
helpful, and in which form (i.e. aerobic and/or progressive resistance) [40]. For a 
long time, exercise training was thought to be harmful in patients whose muscles 
were affected by a neuromuscular disease (NMD), although there was no 
corroborating data. Because affected muscles are already functioning close to its 
maximal limits, exercise training, was for a long time considered to be harmful to 
this damaged muscle tissue. In recent years, however, exercise programs have 
been shown to have a positive effect on muscle strength and endurance of 
patients with NMDs with a similar presentation as Pompe disease, such as 
facioscapulohumeral muscular dystrophy and limb girdle dystrophy  [41]. 
 
 
 
When it comes to Pompe disease, a few studies had been conducted. These 
reported an improvement or stabilization in muscle strength with aerobic 
exercises, either combined with strengthening exercises or a high-protein diet 
[42-45]. Due to the rarity of the disease, these studies were  limited by small 
numbers. Furthermore, the type of exercises used and their intensity and duration 
varied.  In order to strengthen the evidence for exercise training, a study needed 
to be performed in a larger population of adults with Pompe disease. Moreover, 
this could be the starting point for developing guidelines for clinical practice.  
A limitation of exercise training is that it mainly focuses on the ICF level of body 
functions and structures, while patients also experience limitations at the activity 
level [22]. Physiotherapeutic care focuses on all levels of the ICF model. Besides 
maintaining and optimizing bodily functions it also teaches patients to deal with 
limitations at the activity and participation level. Furthermore, the ICF model 
considers human functioning as an intricate interplay between all three levels as 
well as with personal and environmental factors. Understanding how these levels 
work together could help physiotherapists to focus their treatments better. For 
example, it would be helpful to have insight into the extent to which activities, 
such as walking performance, can be explained by variables on the other levels of 
the ICF model. As patients with Pompe disease have indicated that they consider 
walking performance to be the most restricted activity in daily life [22], it would 
make sense to start with unravelling the determinants of walking performance. 
Exercise training can be focused on improving a patients’ functioning in general, 
or be more specifically focused on a few specific muscles or functions, like 
walking. Such targeted exercises of specific muscles can also be effective in 
treating other symptoms related to Pompe disease, such as incontinence or 
respiratory function. Incontinence has been reported as a problem in Pompe 
 
 
 
disease [46-48], but its occurrence in the Dutch Pompe population is unclear. 
Pelvic floor physiotherapy (PFPT) addresses (amongst others) specific weakness of 
the pelvic floor muscles and could be beneficial for Pompe patients suffering from 
incontinence. However, like generic physiotherapy, pelvic floor physiotherapy is a 
relatively unknown treatment option in patients with Pompe. At present there is 
no evidence of the added value of pelvic floor physiotherapy in Pompe patients, 
although this has been shown for the general population.  
 
  
 
 
 
AIMS AND OUTLINE OF THIS THESIS 
This thesis comprises a number of studies aimed to investigate whether 
physiotherapeutic care of patients with Pompe disease can be a valuable addition 
to the existing enzyme replacement therapy.  
Chapter 2 and 6 provide an overview of the contemporary physiotherapy practice, 
both regular and specifically aimed at the pelvic floor muscles, in adult patients 
with Pompe disease in the Netherlands. Chapter 3 and 4 report on the feasibility 
and safety performing a standardized and well-structured exercise program 
combining aerobic, resistance and core stability exercises adjunct to enzyme 
replacement therapy. Whereas chapter 3 focuses on endurance, muscle strength, 
core stability and functional activity is the focus in chapter 4  on fatigue, pain, 
physical and mental functioning. In chapter 5 we study factors that influence 
walking performance in adult patients with Pompe disease, including muscle 
strength, BMI and ventilator dependency. Chapter 6 focuses on the prevalence 
and characteristics of incontinence in Dutch adult patients with Pompe disease. 
The general discussion, chapter 7, gives an on overview of the results and outline 
directions for future research in the field of physiotherapy in Pompe disease.  
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ABSTRACT  
 
Pompe disease is an inherited metabolic, neuromuscular disorder. With the 
introduction of enzyme replacement therapy skeletal muscle and respiratory 
function can be stabilized or improved. Additional physiotherapy to advance 
physical functioning of patients might be beneficial, but evidence and guidelines 
are lacking. 
In order to get an insight into current practices of referral and treatment, and 
perceived benefit, we performed a survey among 88 Dutch adult Pompe patients 
and 31 physiotherapists. 
Sixty percent of patients were ever referred for physiotherapy, whereas currently 
less than 40% receive physiotherapy. Approximately 50% of patients were 
referred for loss of muscle strength; while 74% received muscle strengthening 
exercises, often combined with aerobic endurance training. In 47% of patients the 
intervention did not match the referral reason. More than two-thirds of patients 
and physiotherapists perceived physiotherapy as beneficial, and the majority 
highlighted the need for guidance. 
Physiotherapeutic care can be improved by tailoring interventions to referral 
reasons and treatment objectives. More high quality studies are urgently needed 
to assess which interventions are most useful in this patient group. 
 
 
  
INTRODUCTION  
 
Pompe disease is a neuromuscular disorder caused by a deficiency of lysosomal 
alpha-glucosidase. Depending on age of onset, it can be classified as an infantile, 
childhood, or an adult phenotype. The disease presents as a broad clinical 
spectrum, ranging from severe generalized hypotonia and hypertrophic 
cardiomyopathy in the infantile form, to a slowly progressive proximal myopathy 
in late-onset Pompe disease. The proximal myopathy seen in adult patients is 
mainly related to skeletal muscle dysfunction. It causes both mobility and 
respiratory problems and eventually leads to wheelchair and/or ventilator 
dependency. Pompe disease used to be an untreatable disease but the 
introduction of enzyme replacement therapy (ERT) with human recombinant 
Alglucosidase alfa (Myozyme®) has improved the prospects of patients. ERT has 
shown to improve survival and motor outcome in patients with the infantile 
phenotype [1-3] and to improve walking distance, and stabilize respiratory 
function in patients with the late onset phenotype[4-6]. 
Previously a sedentary lifestyle was recommended to prevent overuse of the 
damaged muscle tissue [7]. In recent years, exercise programs have been shown 
to have a positive effect on muscle strength and endurance in patients with 
related neuromuscular disorders (NMD) [8]. In addition, an observational study on 
the effect of ERT in Pompe patients reported better functional outcomes for those 
who specifically subscribed to physiotherapy [4]. These promising results together 
with the advent of ERT have resulted in an increased demand for physiotherapy 
interventions in Pompe patients.  
Despite its assumed added value, scientific evidence for the effectiveness of 
physiotherapy in Pompe disease is lacking. Consequently, there is no consensus 
regarding the most efficient physiotherapy interventions for Pompe disease and 
guidelines are lacking. As a first step towards the development and evaluation of a 
physiotherapy program adjunct to ERT it is important to gain insight into the 
current practices and perceptions.  
We conducted a survey among all Dutch late-onset Pompe patients and their 
therapists to gain insight into the extent of referral to physiotherapy, types of 
physiotherapy interventions currently being used and their specifications as well 
as their perceived effect. 
 
  
MATERIALS AND METHODS  
This study took place within the context of a larger study on the natural course 
and effects of ERT in adult Pompe patients at the Erasmus MC University Medical 
Center Rotterdam. This is the Dutch national referral centre and an international 
expert centre for Pompe disease. All patients provided written informed consent. 
SUBJECTS 
PATIENTS  
All 90 adult patients with a confirmed diagnosis of Pompe disease seen in the 
Erasmus MC between April and August 2009 (i.e. the entire Dutch adult Pompe 
population known at the time) were included. Of these, 78 visited the outpatient 
clinic and the 12 remaining patients were contacted by telephone. Two patients 
were unable to speak by telephone because of invasive ventilation. Therefore, 88 
patients were enrolled in this study. The patients were categorized into those ever 
receiving physiotherapy and those who never received physiotherapy. 
PHYSIOTHERAPISTS 
 Patients who had ever received physiotherapy to treat symptoms related to 
Pompe disease were asked for permission to contact their therapist. All patients 
agreed and, subsequently, a questionnaire was sent to their therapists. Eleven out 
of 52 were not traceable, and 10 did not respond, so finally 31 therapists were 
included in this study. 
  
MEASUREMENTS  
PATIENTS  
Using a custom made questionnaire, information on referral (referring specialist, 
reason for referral or non-referral), perceived effect of the physiotherapy 
intervention and the need for guidelines was obtained. Patients received the 
questionnaire during regular history-taking, or over the phone. Information on 
age, gender, year of first symptoms, year of diagnosis and use of walking aids, 
wheelchair or ventilator were collected as part of the larger study on Pompe 
patients in the centre. 
PHYSIOTHERAPISTS  
Another custom made questionnaire was sent out to the therapists. It covered the 
same topics as the patients' questionnaire supplemented by questions on 
objective, type and specifications (frequency, duration, intensity) of interventions, 
evaluation procedures, and reasons for ending treatment. The type of 
intervention was divided into seven intervention categories: (1) aerobic exercises, 
(2) muscle strengthening exercises, (3) respiratory care, (4) mobilization 
techniques (i.e. maintenance of range of motion), (5) massage therapy, (6) 
practicing functional tasks (i.e. sit-to-stand transfer) or (7) others. 
Both questionnaires consisted of closed-ended questions, with dichotomous or 
multiple answer options. 
ANALYSIS 
 Demographic data were summarized and the referred and non-referred group 
compared using Mann–Whitney and chi-square tests as appropriate. Because 
disease severity may affect the choice of treatment goals and interventions, 
responses were compared between mildly affected patients (walking with or 
without aids and no ventilator use) and moderate to severely affected patients 
(wheelchair bound and/or ventilator use). 
Descriptive statistics were performed with SPSS 16.0 for Windows software (SPSS, 
Inc., Chicago IL). 
 
RESULTS  
PATIENT CHARACTERISTICS 
Of the 88 included Pompe patients 32 (36.4%) received physiotherapy for the 
treatment of symptoms of Pompe disease at time of this study; 20 (22.7%) had 
received physiotherapy in the past and stopped, and 36 patients (40.9%) had 
never been referred for physiotherapy. Table 1 presents the characteristics of the 
included patients. Patients had a median disease duration of 16.5 years (3–53) 
and 85% of them had started ERT. Those referred to a physiotherapist had a 
notably longer disease duration and were more dependent on walking aids or 
wheelchair compared to those who had never been referred (p = 0.03 and p = 
0.02, respectively). On the other hand, inspecting those patients who were 
independent on walking aids, about half were referred and half never referred (23 
and 27 patients, respectively). 
  
Table 1 | Characteristics of Dutch adult Pompe patients (N = 88). 
 Total 
N = 88 
Ever PT 
N = 52 
Never PT 
N = 36 
P-value* 
     
Gender, male (N (%)) 42 (47.7) 23 (44.2) 19 (52.8) 0.430 
Age in years (median (range)) 53.0 (25–
76) 
53.0 (29–
76) 
51.5 (25–
74) 
0.842 
Disease duration in yrs (median 
(range)) 
16.5 (3–53) 19.5 (6–45) 13.0 (3–53) 0.030 
     
Mobility (N (%)):    0.02 
- no walking aids 50 (56.8) 23 (44.2) 27 (75.0)  
- use of walking aids 14 (15.9) 10 (19.2) 4 (11.1)  
- partial wheelchair use 7 (8.0) 6 (11.5) 1 (2.8)  
- permanent wheelchair use 17 (19.3) 13 (25.0) 4 (11.1)  
     
Ventilator use (N (%)):    0.170 
- no ventilator use 64 (72.7) 35 (67.3) 29 (80.6)  
- non-invasive use 18 (20.5) 12(23.1) 6 (16.7)  
- invasive use 6 (6.8) 5 (9.6) 1 (2.8)  
Physiotherapy (N (%)):    N/A 
- never 36 (40.9) N/A 36  
- at present 32 ( 36.4) 32 N/A  
- stopped with treatment 20 (22.7) 20 N/A  
PT: physiotherapy, N/A: not applicable.                                                                                                                                
* P-value for the difference between ever and never treated patients using chi-square test 
or for age and disease duration, the Mann–Whitney U test. 
 
The 20 patients who stopped physiotherapy were significantly more often 
ventilator dependent than patients who were receiving physiotherapy at the time 
of this study (50% versus 22%, p = 0.04). There were no significant differences 
between these groups regarding use of walking aids and disease duration. 
 
REFERRAL CHARACTERISTICS AS REPORTED BY PATIENTS 
Most patients had been referred by either their neurologist (49.1%) or general 
practitioner (23%). Table 2 shows the reasons for referral according to the 
patients. Overall, the main referral reasons were loss of muscle strength (52%), 
loss of general condition (40%) and pain (25%). In severely affected patients 
problems with activities of daily living (ADL) (27%) also played a large role. 
Twenty-five patients had more than one reason for referral (mean 1.60; range 1 
to 3). Muscle weakness and decrease of general condition was the combination 
most commonly seen (25%). 
 
Table 2 | Reasons for referral to physiotherapy for Dutch adult Pompe patients. 
 Total N (%) 
N = 52 
Mild N (%) 
N = 30 
Moderate–severe N 
(%) 
N = 22 
    
Muscle weakness 27 (51.9) 14 (46.7) 13 (59.1) 
Loss of general 
condition 
21 (40.4) 13 (43.3) 8 (36.4) 
Pain 13 (25.0) 8 (26.7) 5 (22.7) 
Problems with ADL 9 (17.3) 3 (10.0) 6 (27.3) 
Stiffness 7 (13.5) 4 (13.3) 3 (13.6) 
Other 4 (7.7) 2 (6.7) 2 (9.1) 
Pulmonary problems 3 (5.8) 1 (3.3) 2 (9.1) 
ADL: activities of daily living.  More than one reason can be stated so percentages add up 
to more than 100%. 
 
The most frequent reason (78%, 28/36) for not being referred to physiotherapy 
was that patients did not experience restrictions in daily life. Two patients were 
told that physiotherapy was harmful and six patients could not explain why they 
never received physiotherapeutic care. 
TREATMENT CHARACTERISTICS REPORTED BY PHYSIOTHERAPISTS 
Patients were treated one to three times per week (median 1) and the duration of 
one treatment varied from 12 to 60 min (median 30). The median duration of the 
treatment period was 12 months (range 1–180). 
Table 3 shows the main treatment objectives and interventions. The most 
common treatment goals were to improve muscle strength (81%), walking (68%), 
and general condition (42%). For each patient the therapists formulated at least 
two objectives. 
Overall, the most frequently used interventions were muscle strengthening 
exercises (MSE, 74%), aerobic exercise therapy (AET, 68%) and home exercise 
program (HEP, 68%). The HEP covers a wide range of different exercises 
performed at home, without supervision of a therapist, and often included 
mobilization, walking and strengthening exercises. In addition, mobilization 
techniques and massage therapy (MT, 53%) were frequently used in mildly 
affected patients for reducing stiffness and pain. Training of activities of daily life 
(ADL, 67%) was regularly applied in more severely affected patients. Most 
patients received more than one intervention (mean 2.5; range 1–5), the most 
common combination being MSE with AET (61%). 
  
Table 3 | Treatment objectives and interventions used, reported by 31 therapists, for 
mild and moderately to severely affected adult Pompe patients. 
AL: activity level; BL: body level; STS: sit to stand movement. More than one option could 
be stated so percentages add up to more than 100%. 
 
 
 
  
 
Improvement of: 
Total  
N (%) 
N = 31 
Mild  
N (%) 
N = 19 
Moderate–severe 
N (%) 
N = 12 
    
Objectives     
Muscle strength (BL) 25 (80.7) 15 (78.9) 10 (83.3) 
Walking (AL) 21 (67.8) 12 (63.2) 9 (75.0) 
General condition (BL) 13 (41.9) 8 (42.1) 5 (41.7) 
STS (AL) 10 (32.3) 7 (36.8) 3 (25) 
Muscle coordination (BL) 9 (29.0) 6 (31.6) 3 (25.0) 
Stair climbing (AL) 9 (29.0) 9 (47.4) 0 (0.0) 
Other (AL) 8 (25.8) 5 (26.3) 3 (25) 
Stiffness (BL) 7 (22.6) 4 (21.1) 3 (25.0) 
Standing (AL) 7 (22.6) 3 (15.8) 4 (33.3) 
Pain (BL) 5 (16.1) 4 (21.1) 1 (8.3) 
Pulmonary status (BL) 3 (9.7) 2 (10.5) 1 (8.3) 
Other (BL) 3 (9.7) 2 (10.5) 1 (8.3) 
Cycling (AL) 2 (6.5) 2 (10.5) 0 (0.0) 
Sitting (AL) 2 (6.5) 1 (5.3) 1 (8.3) 
 
Interventions 
   
Muscle strengthening exercises (MSE) 23 (74.2) 13 (68.4) 10 (83.3) 
Aerobic endurance training (AET) 21 (67.7) 12 (63.2) 9 (75.0) 
Home exercise program (HEP) 21 (67.7) 11 (57.9) 10 (83.3) 
Massage therapy and mobilization 
therapy (MT) 
14 (45.2) 10 (52.6) 4 (33.3) 
Exercises targeting activities in daily 
living (ADL) 
11 (35.5) 3 (15.8) 8 (66.6) 
Respiratory care (RC) 2 (6.4) 1 (5.3) 1 (8.3) 
Other 2 (6.4) 1 (5.3) 1 (8.3) 
REFERRAL AND TREATMENT PATTERNS 
Of the 20 patients who were referred because of muscle weakness, 16 (80%) had 
muscle strength improvement as a treatment objective and 14 (70%) received 
MSE. Thirteen patients were referred for improving general condition, whereas 
nine (69%) had this as a treatment goal and eight (62%) received AET for 
improving the general condition. Overall we saw a discrepancy between referral 
reason and objective in 32% of cases, while in 47% the referral reason and 
intervention were not aligned (Fig. 1). 
     
 
 
 Fig. 1 | Referral and treatment patterns reported by 31 therapists.  
MSE: muscle strengthening exercises, AET: aerobic exercise therapy,                                    
MT: massage/mobilization techniques. For reason for referral that is more than N= 5. 
 
EFFECT OF TREATMENT AND NEED FOR GUIDELINES 
All patients (n = 52) who ever received physiotherapy were asked if, in their 
opinion, physiotherapy resulted in the desired effect. One patient could not 
indicate this because therapy had just started. Overall, 60% of patients responded 
positively to this question (66% of mildly affected and 46% of more severely 
affected patients, p > 0.1). 
Patients receiving physiotherapy at the time of this study more often perceived 
the intervention to have the desired effect than those who stopped (72% versus 
30%, p = 0.01). Eleven of the 20 patients who had stopped did so because of a lack 
of effect or negative side-effects such as extreme fatigue, muscle pain or bursitis; 
five (25%) because their rehabilitation program ended after 3 months and 
continuation was not covered by their insurance company; four (20%) had 
reached their treatment goal.  
All 31 therapists were asked if the (intermediate) treatment objectives were 
reached. Nine therapists could not indicate this due to a short treatment period 
(less than 4 weeks). Of the 22 remaining therapists 14 (64%) indicated that 
objectives were reached; two stated that treatment goals were partially reached 
and six stated that they were not reached. Different outcome measures were 
used.  
Due to the multiple intervention combinations it was not possible to evaluate 
which intervention (or combination) was perceived as most effective. The 
percentages of patients and therapists reporting an effect for MSE, AET, HEP, MT 
and ADL were similar (between 55 and 75%). All therapists except one (97%) and 
73% of patients indicated that there is a need for guidelines for the physiotherapy 
treatment of Pompe patients.  
 
  
DISCUSSION  
This survey shows that physiotherapeutic care of Pompe patients in the 
Netherlands consists of a wide range of treatment interventions. About 60% of 
the patients were ever referred to the physiotherapist, with more severely 
affected patients being referred more often. Referral reasons varied, and were 
not always in line with the interventions used. The most commonly used 
intervention was muscle strengthening exercises (MSE), often in combination with 
aerobic exercise therapy (AET). More than half of the patients and therapists 
perceived physiotherapy as beneficial and the majority highlighted the need for 
guidelines.  
The observed variation in referral reasons and interventions can partly be 
explained by the wide spectrum of symptoms and needs of Pompe patients [9]. 
Nevertheless, the referral pattern was not always consistent with the clinical 
picture of Pompe disease. It is unclear, for example, why half the patients who 
were independent on walking aids were referred to a physiotherapist, while the 
other half were not. In addition, at the moment of this study, less than 40% of the 
Dutch Pompe patients were treated by a physiotherapist. Both observations may 
indicate that there is confusion about the treatment opportunities and their use. 
Both clinicians and patients highlighted the need for guidance, supporting this 
notion. 
The applied intervention could also not always be explained by the clinical picture. 
We observed a discrepancy between the referral reasons, treatment objectives 
and the actual interventions. Only 53% of the treatment interventions and 68% of 
the objectives were in line with the referral reasons. In addition, frequency, and 
duration of interventions varied substantially between patients. Physiotherapists 
have little chance to develop relevant experience with this rare disease, and will 
likely see only one or two Pompe patients during their career, which may explain 
the wide range of interventions and treatment objectives. Personal preference 
and the lack of research evaluating the effectiveness of physiotherapy in the 
management of Pompe disease may further contribute to the wide range of 
interventions and discrepancy. 
A number of studies, mostly hampered by small numbers of patients, have 
investigated the effect of physiotherapy in Pompe disease [10-14]. Three studies 
reporting on the effect of aerobic exercises—either combined with strengthening 
exercises or a high-protein diet—showed either improvement or stabilization in 
muscle strength [10-12]. In two studies respiratory muscle training was described 
to increase respiratory muscle strength [13, 14]. Due to the small numbers of 
patients and the diverse interventions and outcome measures used, firm 
conclusions about the effectiveness of these interventions cannot be drawn. 
Therefore, there is a clear need for further studies on the effectiveness of 
physiotherapy for Pompe patients. 
This is the first study to describe the present physiotherapeutic practice for 
patients with Pompe disease. A limitation of this study was its subjective and 
retrospective character, which might have influenced the reliability of the data. 
More than half of the patients and almost two-thirds of physiotherapists 
perceived physiotherapy as beneficial. Although patients reported a benefit from 
treatment, it was not possible to assess how this corresponded with changes in 
outcomes such as an increase in muscle strength or the ability to do more 
activities in daily living. Moreover, the opinions of therapists were based on 
different outcome measures so the results of their treatment were not mutually 
comparable. Therefore, this study does not allow any statements on the 
effectiveness of interventions or about which intervention (combination) fits 
Pompe patients best. We were also not able to compare the perceived benefit of 
physiotherapy between patients receiving and not receiving ERT due to the small 
number of patients not receiving ERT and differences in disease severity between 
these patient groups. Finally, not all therapists were traceable, reducing the 
number of observations for certain variables. 
Some suggestions can be made however. The observation that mildly affected 
patients reported more benefit than moderate to severely affected patients 
suggests that this group might benefit more from physiotherapy. The most 
commonly used intervention was MSE (74%), and the combination with AET was 
the most frequently applied. Future studies on the effectiveness of physiotherapy 
should have a prospective design with a core set of outcome measures. They 
should focus firstly on the effectiveness of the most frequently observed 
interventions such as AET combined with MSE as an addition to ERT in Pompe 
patients of different disease severity. Further, the development of a 
physiotherapy network consisting of an expert centre and a selected group of 
physiotherapists who see several Pompe patients would ensure that therapists 
are more familiar with the disease as well as form a platform for further studies. 
 
  
CONCLUSIONS 
Physiotherapeutic care of Pompe patients in the Netherlands is perceived as 
beneficial although it is scattered and diverse. The variety in interventions can 
only partly be explained by the heterogeneity of symptoms. Care of patients may 
be sub-optimal and improvements can be made by tailoring interventions to the 
referral reasons and treatment objectives. 
The rarity of the disease and the lack of scientific evidence and guidelines hamper 
further optimization of treatment. However, due to the wide clinical spectrum of 
the disease it is difficult to make a uniform treatment program. Therefore, clinical 
trials are urgently needed, exploring the type and content of interventions that 
are most beneficial to Pompe patients in different stages of disease severity.  
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ABSTRACT  
 
BACKGROUND 
Pompe disease is a proximal myopathy. We investigated whether exercise training 
is a safe and useful adjuvant therapy for adult Pompe patients, receiving enzyme 
replacement therapy. 
METHODS 
Training comprised 36 sessions of standardized aerobic, resistance and core 
stability exercises over 12 weeks. Before and after, the primary outcome 
measures safety, endurance (aerobic exercise capacity and distance walked on the 
6 min walk test) and muscle strength, and secondary outcome measures core 
stability, muscle function and body composition, were evaluated. 
RESULTS 
Of 25 patients enrolled, 23 successfully completed the training. Improvements in 
endurance were shown by increases in maximum workload capacity (110 W 
before to 122 W after training, [95 % CI of the difference 6 · 0 to 19 · 7]), maximal 
oxygen uptake capacity (69 · 4 % and 75 · 9 % of normal, [2 · 5 to 10 · 4]), and 
maximum walking distance (6 min walk test: 492 meters and 508, [−4 · 4 to 27 · 7] 
). There were increases in muscle strength of the hip flexors (156 · 4 N to 180 · 7 N 
[1 · 6 to 13 · 6) and shoulder abductors (143 · 1 N to 150 · 7 N [13 · 2 to 35 · 2]). As 
an important finding in secondary outcome measures the number of patients who 
were able to perform the core stability exercises rose, as did the core stability 
balancing time (p < 0.05, for all four exercises). Functional tests showed small 
 
 
reductions in the time needed to climb four steps (2 · 4 sec to 2 · 1, [− 0 · 54 to 
−0 · 04 ]) and rise to standing position (5 · 8 sec to 4 · 8, [−2 · 0 to 0 · 0]), while time 
to run, the quick motor function test results and body composition remained 
unchanged. 
CONCLUSIONS 
Our study shows that a combination of aerobic, strength and core stability 
exercises is feasible, safe and beneficial to adults with Pompe disease. 
  
 
 
BACKGROUND  
Pompe disease (glycogen storage disease type II, acid maltase deficiency) (OMIM 
# 232300) is a rare metabolic myopathy caused by glycogen accumulation 
resulting from deficiency of lysosomal acid α-glucosidase (GAA). It presents as a 
wide clinical spectrum, the most prominent symptoms in adults being proximal 
skeletal muscle weakness and respiratory problems [1, 2]. Skeletal muscle 
weakness typically fits a pattern of limb-girdle myopathy, with the abdominal and 
paraspinal muscles and the musculature of the hip being the most affected 
muscle groups [3-5]. 
Enzyme replacement therapy (ERT) with recombinant human acid α-glucosidase 
(Myozyme/Lumizyme) was approved for the treatment of Pompe disease in 2006. 
In adults, ERT has been shown to elicit positive effects on skeletal muscle 
strength, walking distance, respiratory function and survival [6-8]. Patients’ fitness 
and physical functioning may be further supported by treatments additional to 
ERT, such as exercise training. Although some recent studies suggest that exercise 
training may be beneficial, evidence is still limited [9, 10].  
A recent study on common clinical practice in the Netherlands showed that there 
is a lack of uniformity in the type of physical therapy training programs applied, 
and that physical therapists and patients all seek guidance and standardization 
[11]. We therefore aimed to determine whether a standardized and well-
structured exercise intervention program combining aerobic, resistance and core 
stability exercises was feasible and safe, and whether it added value to treatment 
with ERT alone. In a group of relatively mildly affected adult Pompe patients 
receiving ERT for more than a year, we evaluated the effects of such a regime on 
endurance, muscle strength and function, core stability, and body composition. 
 
 
METHODS  
PATIENTS  
Patients were recruited at the Centre for Lysosomal and Metabolic Diseases, 
Erasmus MC University Medical Centre, Rotterdam, the Dutch national referral 
centre for patients with Pompe disease. 
There were three inclusion criteria: 
1. A confirmed diagnosis of Pompe disease measured by decreased acid α-
glucosidase activity in leukocytes or fibroblasts, and mutation analysis; 
2. Age > 17 years; 
3. Treatment with ERT for at least 52 weeks 
There were four exclusion criteria: 
1. The use of walking-aids or a wheelchair; 
2. Ventilator-dependency; 
3. Concurrent medical conditions; 
4. Participation in other exercise-training programs. 
The study was approved by the Ethical Committee at Erasmus MC University 
Medical Centre. Informed consent was obtained from all patients. 
 
 
 
 
 
STUDY DESIGN AND INTERVENTION 
Three times a week for 12 weeks, all patients followed a standardized training 
program that was provided under the supervision of physical therapists at 
carefully selected sports or fitness centres near the patients’ homes. To ensure 
the uniformity of the program and its supervision, all therapists attended a one-
day instruction program at Erasmus MC University Medical Centre. The training 
program is depicted in Fig. 1. The first training session was on-site supervised by 
one of the researchers from Erasmus MC (LvdB, MF), who subsequently attended 
each training site every two weeks to monitor proper conduct of the program. 
Patients were randomly subdivided into two groups: group 1 (n = 13), which 
started the training program at week 1; and group 2 (n = 12), which started at 
week 13. The staggered start of training allowed us to investigate whether any 
improvement observed in the training period could also be attributed to ERT. 
Furthermore, the duration of the effect of the training program can be evaluated 
from the follow-up of patients in group 1 after they stop training in week 12. 
To assess the effects of the program, each patient visited our centre (Erasmus MC) 
on two separate days in weeks 0, 12 and 24. The primary endpoints of this study 
were safety, endurance and muscle strength. Secondary endpoints were core 
stability, muscle function, and body composition.  
Under the supervision of the physical therapist, training diaries were kept by all 
patients, who recorded the days on which they trained, the weight and number of 
repeats of resistance exercises, and the perceived level of exertion. To evaluate 
training progress and patients’ motivation, patients were telephoned weekly. 
  
 
 
 
Figure 1 | Flowchart for the standardized exercise-training regime combining aerobic, 
resistance and core stability exercises 
 
 
ASSESSMENTS  
SAFETY 
Plasma CK was measured every two weeks as a safety marker for exercise-induced 
muscle damage [12], and patients were contacted every week to record potential 
side effects such as pain and fatigue. 
ENDURANCE  
Aerobic (endurance) exercise capacity was determined using an incremental cycle 
ergometer. After 4 min of unloaded cycling on the cyclo ergometer (Jaeger ER 
800; Erich Jaeger, Würzburg Germany) exercise intensity was increased 
progressively until exhaustion (i.e. ramp protocol), during continuous 
measurement of patients’ heart rates and ventilator parameters using spiro 
ergometry equipment (Oxycon Pro, Jaeger, Würzburg, Germany). The rate of 
increase was determined considering the patient’s functional capacities and 
ranged from 5–20 Watts/minute. The duration of every individual test exceeded 6 
min but did not take longer than 12 min. At exhaustion, the rating of exertional 
symptoms was assessed using the Borg scale (scale 6–20) [13], patients 
consistently scoring 14 or above. Maximum workload capacity (WMAX) and, peak 
oxygen uptake capacity (VO2 PEAK) were measured. The ventilatory threshold 
(VT) was assessed independently by two clinical exercise physiologists using the 
ventilatory equivalents method [14]. The test was considered to be maximal when 
one of the following criteria was met [14]: 
1. heart rate > 90 % of that predicted, 
2. respiratory exchange ratio (RER) > 1 · 11, or 
3. VO2 stabilized despite increased workload. 
 
 
Walking distance on the 6-min walk test (6MWT) was evaluated according to the 
American Thoracic Society guidelines. 
CORE STABILITY 
To assess the dynamic balance, which reflects core stability, one physical therapist 
(MF) measured time in balance (in seconds) for each of the four core stability 
exercises of the training program (Fig. 1) [15]. 
MUSCLE STRENGTH 
Muscle strength was assessed by one investigator (SW) using Hand-held 
Dynamometry (HHD). Assessments were performed in a standardized manner, 
and sum scores were calculated as described previously [6]. 
MUSCLE FUNCTION 
Functional activity assessments comprised three timed tests: 10 meter running, 
climbing four steps, and rising from supine to standing positions [16], and the 
Quick Motor Function Test (QMFT), a test specifically designed and validated for 
Pompe patients [17]. The QMFT consists of 16 specific motor skills related to daily 
activities. A total score is achieved by summing the scores for each item (ranging 
from 0 “cannot perform” to 4 “can perform with no effort”), and is expressed as a 
percentage of the maximum score. 
BODY COMPOSITION 
Bone-mineral density (BMD) and body-composition measurements were 
performed conform DXA technology using a Lunar DPX densitometer and 
analysed with Encore 2002 software (GE Lunar DPX, GE Health Care). Bone 
densitometry was performed in a standardized manner as described previously 
 
 
[18]. Body composition was described in terms of the mineral, lean and fat body 
mass (kilograms). The percentage of fat mass and, more specifically, android and 
gynoid fat, were calculated. 
STATISTICAL ANALYSIS 
Patient characteristics were summarized using descriptive statistics. Data for the 
two groups were combined after verifying that there were no significant 
differences between outcome measures before the start of the training (group 1 – 
week 0; group 2 – week 12; student’s t-test for normally distributed, and Mann–
Whitney for not-normally distributed data). 
Mean differences before and after the training were compared using the paired t-
test for normally distributed data, and otherwise the Wilcoxon signed rank test 
for paired samples. For group 2, we also used these tests to compare the outcome 
measures before and after 12 weeks of ERT only (week 0 to 12).  
Significance level was set at p < 0 · 05. Statistical analyses were performed using 
SPSS for Windows (release 17 · 0; SPSS, Inc., Chicago, IL). 
 
RESULTS  
PATIENTS  
A total of 25 patients fulfilled the inclusion criteria and chose to participate in this 
study. Two patients did not complete the training program because they were 
insufficiently motivated. This left 23 patients, who successfully completed the 
study. Their ages ranged from 20 to 71 years (median of 46 years). They had been 
receiving ERT for 1 to 6 years with a median of 3 years (Table 1). 
 
 
Table 1 | Patient characteristics 
 Group 1 
(n=12) 
Group 2 
(n=11) 
Total group 
(n=23) 
P-value 
* 
     
Male gender (%) 
Age in years (range) 
7 (58%) 
45.4 (19.6-
70.5)) 
5 (45%) 
46.6 (32.9-
66.1) 
12 (52%) 
46.0 (19.6-70.5) 
0.54 
0.85 
Disease duration in years 
(range) 
15.5 (8.1-28.1) 16.1 (6.0-
32.1) 
15.8 (6.0-32.1) 0.83 
ERT duration in years 
(range) 
3.3 (1.4-6.5) 3.0 (1.3-3.6) 3.1 (1.3-6.5) 0.96 
Training sessions (max. 
36) 
33 (27-36) 32 (24-35) 32 (24-36) 0.70 
Group 1 trained in weeks 1–12 and Group 2 trained in weeks 13–24                                                                        
ERT enzyme replacement therapy                                                                                                                                          
*  For the difference between group 1 and 2 (chi-2 test for proportions and Wilcoxon 
signed rank test for continuous data) 
 
EFFECT OF ERT ONLY 
During the 12 weeks before training started, patients in group 2 (ERT only) 
underwent the same set of assessments as in the 12 weeks of training (ERT plus 
training). This enabled us to use group 2 to compare the effects of ERT only with 
the combined effects of ERT and training. During the first 12 weeks of ERT only, 
we detected no significant improvements in the main outcome measures. 
EFFECT OF TRAINING 
Patients in the two randomly assigned groups were comparable in terms of age, 
gender, disease duration, time on ERT, number of training sessions completed, 
and baseline test results. This allowed us to analyse the effect of training in the 
total group of 23 patients. 
  
 
 
SAFETY 
During the first week of training, two patients had a high plasma CK level (10125 
U/l and 6149 U/l), and also experienced muscle pain and fatigue. Over the 
following week, their CK-values dropped to their normal range, and the fatigue 
and pain disappeared. Both patients continued training. None of the other 
patients had pain, fatigue, or increases in plasma CK levels during the study 
period. 
ENDURANCE 
All patients were able to complete the incremental cycle test without adverse 
events. One was excluded from the analysis because he did not reach the required 
maximum intensity defined in the method section. After 12 weeks of training 
WMAX, VO2peak and VT improved significantly (Table 2). VO2peak and VT 
increased both in absolute values and adjusted for body weight or as a percentage 
of normal values. The ratio VT/VO2peak did not change, as both the numerator 
and the denominator increased. There were no significant differences between 
patients’ maximum heart rates before and after 12 weeks of training, indicating 
that the results were truly based on an increase in fitness rather than on greater 
exertions by the patients towards the end of the training period. FVC did not 
change. Average walking distance on the 6MWT increased by 16 meters ([4.4-
27.7], p = 0.01). 
 
 
 
 
  
 
 
Table 2 | Aerobic fitness measured in an incremental cycle test and a 6-min walk test 
before and after 12 weeks of training 
 * For the difference before and after training (paired samples t-test)                                                                            
a  One patient was excluded because he did not reach the required maximum intensity 
 
  
 Before 
training 
Mean ± SD 
After training 
Mean ± SD 
P-value * 
    
Incremental cycle test (N = 22a)    
Ventilatory threshold (VT)    
- Absolute values (l/min) 1.25 ± 0.36 1.38 ± 0.36 <0.01 
- Adjusted for body weight 
(ml/min/kg)) 
16.7 ± 4.3 18.5 ± 4.7 <0.01 
- VT/VO2 peak (%) 77.6 ± 12.1  78.3 ± 12.3 0.742 
Data at exhaustion    
- Maximum workload (Wmax, 
Watt) 
110 ± 52 122 ± 53 <0.01 
- Maximum heart rate (bpm) 156 ± 25 161 ±20 0.16 
- Pulmonary ventilation (l/min) 59.6 ± 20.2 68.2 ± 21.0 <0.01 
- Tidal volume (l) 1.85 ± 0.48 1.85 ± 0.44 0.91 
- Gas exchange ratio 1.15 ± 0.09 1.14 ± 0.08 0.71 
Peak oxygen uptake (VO2 peak)    
- Absolute values (l/min) 1.67 ± 0.62 1.82 ± 0.60 <0.01 
- Adjusted for body weight 
(ml/min/kg) 
22.1 ± 7.0 24.1 ± 7.1 <0.01 
- As % of normal 69.4 ± 17.4 75.9 ± 18.0 <0.01 
6 min walk test (N=22)    
- Maximum walking distance 
(6MWT, m) 
492 ± 89 508 ± 97 0.01 
Pulmonary function test (N=23)    
- Forced vital capacity (FVC, % of 
normal) 
89.2 ± 12.6 90.0 ± 14.0 0.51 
 
 
CORE STABILITY 
Figure 2 shows the results of the core stability tests. At the start of the program, 
many patients experienced difficulties in performing the core stability exercises, 
reporting problems with initiating movement and controlling balance. During the 
training program, the number of patients who were able to perform the exercises 
increased for three of the four exercises (from 17 to 21 for the abdominal bridge, 
15 to 16 for the left side bridge and 13 to 16 for the right side bridge). The average 
time they were able to remain in balance improved for all four positions (by 58 % 
for the back bridge, 229 % for the left and 223 % for the right side bridges, and 86 
% for the abdominal bridge; p < 0 · 05). 
 
 
Figure 2 | Time patients (N = 23) were able to remain in balance for the four different 
core stability exercises before (white bars) and after training (black bars) 
 
  
 
 
MUSCLE STRENGTH 
Of the nine muscle groups tested, there were increases in the strength of the hip 
flexors and shoulder abductors (Table 3). 
Table 3 | Muscle strength measured by hand-held dynamometry (HHD) before and after 
12 weeks of training 
HHD of individual 
muscle groups in 
Newton (N=23) 
Before training 
Mean ± SD 
After training 
Mean ± SD 
P-value * 
Neck extensors 142.1 ± 18.4 140.4 ± 13.8 0.65 
Neck flexors 124.7 ± 40.2 132.1 ± 33.9 0.09 
Shoulder abductors 143.1 ± 29.1 150.7 ± 35.4 0.02 
Elbow flexors 226.4 ± 41.5 230.8 ± 42.3 0.42 
Elbow extensors 180.5 ± 20.1 176.2± 25.3 0.27 
Hip flexors 156.4 ± 61.9 180.7 ± 57.7  < 0.01 
Hip abductors 159.4 ± 58.3 158.0 ± 68.1 0.75 
Knee extensors 189.2 ± 34.1 193.0 ± 31.8 0.27 
Knee flexors 121.2 ± 56.2 122.6 ± 56.7 0.51 
*For the difference before and after training (paired samples t-test 
 
MUSCLE FUNCTION 
Twelve weeks of training significantly reduced the time taken by patients to climb 
four steps (on average 0.3 sec less, [−0 · 54 to −0 · 04], p = 0.02 Table 4) and to rise 
from supine to a standing position (1 sec less, [−2.0 to 0 · 01], p = 0.05). The QMFT 
sum score and the time to run 10 meters did not change. 
 
  
 
 
Table 4 | Muscle function measured by the quantitative motor function test (QMFT) and 
timed tests before and after 12 weeks of training 
 Before training 
Mean ± SD 
After training 
Mean ± SD 
P-value * 
QMFT score (N = 22b) 
Timed Test (N = 22b) 
51 ± 8 51 ± 9 0.65 
-    10 m running (sec)a 4.97 ± 1.50 4.70 ± 1.34 0.13 
- Climbing four steps (sec)a 2.37 ± 0.80 2.08 ± 0.74 0.02 
- Rising from supine to 
standing position (sec)a 
5.83 ± 4.25  0.05 
*  For the difference before and after training (paired samples t-test and the Wilcoxon 
signed-ranks test for paired data a)                                                                                                                                                                                  
b QMFT score and timed test were not available for one patient 
 
BODY COMPOSITION 
There were no changes in mineral bone mass (2 · 83 kg ± 0 · 58 before training vs. 
2 · 82 kg ± 0 · 57 after training), in lean body mass (42 · 53 kg ± 7 · 99 vs. 43 · 14 
kg ± 8 · 28), or in fat mass (30 · 11 kg ± 9.23 vs. 29 · 29 kg ± 9 · 06). Likewise, there 
were no changes in bone mineral density, overall fat percentage, and android and 
gynoid fat percentages (results not shown). 
DURATION OF TRAINING EFFECT 
After the initial 12 weeks of training group 1 was planned to discontinue training, 
but 11 of 13 patients chose to continue training with the same or slightly modified 
intensity. Therefore we were not able to assess how long the training effect 
maintained after withdrawal. 
 
  
 
 
DISCUSSION  
This study provides clinical evidence that a combination of aerobic, resistance and 
core stability training can be performed safely in patients with Pompe disease, 
and helps to improve endurance, core stability and muscle function. 
Improved endurance was shown by improved aerobic fitness over 12 weeks of 
training. In addition to the 11 % increase in maximum workload capacity, peak 
oxygen uptake and ventilatory threshold improved by 9 % and 10 %, and the 
6MWT by 3 %. The increase in peak oxygen uptake was relatively small compared 
to a number of studies in neuromuscular dystrophies and metabolic myopathies 
like McArdle disease, showing an increase ranging from 12-47 % [19-22]. In these 
studies, patients spent more time per week on endurance training, which might 
explain the larger increase. A second explanation might be the lower baseline 
VO2peak than in our study. 
The baseline values on VO2peak we found in our study were slightly higher than 
those reported in two Italian studies of Pompe patients (range 15.1 – 26.4 
ml/kg/min) [23, 24]. These include 8 patients who were assessed prior to 
treatment (median 20.5 mg/kg/min), and one patient assessed during ERT (15.7 
mg/kg/min), while all our patients had been on ERT for at least a year, which 
might explain the somewhat higher VO2peak values in our cohort. Nevertheless, 
our 6MWT results also suggest that our cohort had a relatively good endurance 
capacity before the training (77 % of normal expected). Finally, their ventilatory 
threshold as a percentage of the peak oxygen uptake (78 %) is relatively high for 
an untrained population, and comparable to that seen in the three Italian patients 
that reached the VT (five did not reach the VT in this study, while all our patients 
reached VT). Our patients thus had relatively good endurance and tolerance 
 
 
capacity before training, which is in agreement with the fact that mildly affected 
Pompe patients were selected for this study. 
So far the 6MWT was used in clinical trials for Pompe disease to assess endurance 
capacity, but since most patients have walking difficulties it has been questioned 
whether the 6MWT fully reflects this [25, 26]. Our study indicates that the 
incremental cycle test offers a good alternative to test endurance capacity, 
providing insight into patients’ aerobic capacity. 
Core stability has not been trained previously in neuromuscular disorders 
presenting with limb-girdle weakness. One possible reason may lie in the 
assumption that core stability exercises are not feasible for such patients. Indeed, 
on starting training, many patients had difficulty performing the exercises. During 
the program, however, they learned to activate the proper muscle groups and 
were able to remain in balance for longer. Our results thus indicate that core 
stability training is feasible and improves time in balance in patients with Pompe 
disease who are treated with ERT. Feedback from patients during the training also 
suggests that they perceived their improved core stability to facilitate daily 
activities. Further studies on how training influences patient reported outcomes 
such as quality of life are needed. 
An increase in muscle strength was observed in two of the nine muscle groups 
tested: the hip flexors and shoulder abductors. We are not completely certain 
whether the increased strength of the hip flexors resulted from strength training, 
core stability exercises, or both. Core stability may support gains in muscle 
strength by improving proprioception and coordination. 
The combined effects of the training program on endurance, core stability, and 
muscle strength also led to some functional improvement, with patients 
becoming able to climb four stairs and rise to a standing position faster. 
 
 
In our study all patients received enzyme replacement therapy. It has been 
reported that the main incremental effects of enzyme replacement therapy (ERT) 
are observed during the first year. Therefore only patients who had received ERT 
more than 1 year were allowed to participate. The study had a staggered design 
with patients in group 2 starting after a period of no training allowing evaluation 
of the effect of ERT only, and patients in group 1 scheduled to stop training after 
12 weeks with the intention to study how long the effect of training continued. 
During ERT only patients remained more or less stable indicating that training was 
the main driver behind the effects. We were not able to assess how long the 
training effect continued, since all patients in group 1, except two, chose to 
continue training after 12 weeks. Although patients’ choice interfered with our 
study design, it also reflects the positive feedback they have given us on the 
program. 
Compliance was high in our study. It is likely that the beneficial effects 
experienced, the supervision by physiotherapists and weekly telephone 
consultations contributed to this. We therefore recommend that the program be 
incorporated into regular supervised physiotherapy sessions. 
Few studies have been conducted on exercise and training in Pompe disease. The 
largest so far was performed before ERT became available [9]. For a mean 
duration of four years, 26 patients participated in a combined nutrition and 
endurance exercise therapy program that led to improved muscle function as 
measured with the Walton score. More recently, a German observational study 
showed that the effect of ERT on walking distance was most pronounced in five 
patients who, incidentally, were also subjected to endurance training on a cycle 
ergometer during ERT infusions [10]. Two other studies, one in mice and one in 
five adult patients with Pompe disease, however, did not confirm a beneficial 
effect of endurance training while receiving ERT [27, 28]. 
 
 
Previous exercise studies in Pompe disease mainly focused on endurance training. 
It has been envisaged that resistance training might lead to muscle damage, 
thereby aggravating muscle weakness [29-31]. Prior to our study, only Terzis et al. 
[28] combined endurance with resistance training in five patients with Pompe 
disease receiving ERT. The combined results of these five patients showed that 
both muscular strength and walking distance improved. 
Before starting our study we carefully considered whether we should perform 
exercise-endurance training only, or a combination of different types of exercises. 
We chose the latter, because we not only wanted to improve endurance, but also 
target all affected muscles (resistance exercises), and ameliorate proprioception 
and the strength of those proximal muscles not targeted by resistance training 
(core stability exercises). Our decision to use a combined program was also driven 
by the fact that our patient population was not large enough to run three 
separate programs. 
Although we cannot rule out the possibility that endurance training alone might 
have had a greater impact on endurance, we observed that the extra exercises 
had positive effects on core stability, and may also have improved muscle 
strength and function. Earlier studies in patients with inherited muscular 
myopathies did not include core stability exercises; our study shows them to be 
both safe and easy to learn. Patients in our study were mildly affected; those who 
are more severely affected may need slightly adjusted exercise-training programs 
but we recommend to include similar components. 
 
  
 
 
CONCLUSIONS 
Our study shows that a combination of endurance, strength and core stability 
training is feasible and can be performed safely in patients with Pompe disease. 
Such training helps to improve endurance, muscle strength, muscle function and 
core stability. This training program thus seems to offer added value for Pompe 
patients to those of ERT. 
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ABSTRACT 
OBJECTIVE 
To assess if a 12-week exercise intervention to improve aerobic fitness, muscle 
strength, and core stability also had an impact on fatigue, pain, activity, and 
participation in adults with Pompe disease, an inherited neuromuscular disorder. 
DESIGN 
Open-label trial. Change was assessed by the chi-square test and Wilcoxon signed-
rank test. 
SETTING 
Physiotherapy practices. 
PARTICIPANTS 
Mildly affected adult patients with Pompe disease who were not dependent on 
ventilators and/or walking devices and were receiving enzyme replacement 
therapy. 
INTERVENTION 
Patients participated in a 12-week exercise program, which included 36 sessions 
of standardized aerobic, resistance, and core stability exercises. 
MAIN OUTCOME MEASURES 
Before and after the training program we evaluated fatigue (Fatigue Severity 
Scale), pain (yes/no), motor function (Quantitative Muscle Function Test, Rasch-
 
 
built Pompe-specific Activity Scale), amount of physical activity (activity monitor), 
and health status (Medical Outcomes Study 36-Item Short-Form Health Survey). 
RESULTS 
Of the 25 patients enrolled, 23 completed the program. At the end of the 
program, levels of fatigue (median, 5.33 to 4.78, P=.01) and pain (56.5% to 
21.7%, P=.04) improved. The quality of motor function and the amount of physical 
activity patients engaged in did not change. Changes in pain and fatigue were not 
related to improvements in aerobic fitness or muscle strength. 
CONCLUSIONS 
This study in mildly affected adult patients with Pompe disease suggests that a 
combined training program aiming to increase aerobic fitness, muscle strength, 
and core stability also leads to improvements in fatigue and pain. 
 
  
 
 
Pompe disease is an inheritable neuromuscular disease caused by a deficiency of 
the lysosomal enzyme acid alpha-glucosidase, which results in a glycogen 
accumulation in cells. The disease has a broad clinical spectrum; in adult patients 
it primarily affects skeletal and respiratory muscles [1].  
In 2006, enzyme replacement therapy (ERT) with recombinant human acid alpha-
glucosidase became available. ERT has been shown to improve skeletal muscle 
strength, walking distance, respiratory function, and survival in adult patients [2-
5]. The most prominent effects were obtained in the first year of ERT and 
stabilized thereafter [3]. 
Complementary therapies such as exercise therapy may further enhance patients' 
functioning and quality of life. A few studies have demonstrated a positive effect 
of exercise therapy in Pompe disease [4, 6-8]; no study has reported negative 
effects. However, insufficient conclusions can be drawn from these studies 
because of the combination of exercise training with other adjuvant therapies 
and/or the small number of patients included. Our recently reported controlled 
training study further strengthens the evidence for a beneficial effect of exercise 
training [9]. 
In this recent study, 23 mildly affected patients with Pompe disease receiving ERT 
completed a training program consisting of a combination of aerobic, resistance, 
and core stability exercises [9]. The first report on this study focused on the 
outcomes directly related to the intervention and showed that this training 
regimen resulted in significant improvements in aerobic fitness, muscle strength, 
core stability, and distance walked. These outcome measures mostly represent 
functioning at the body function and structure level as described in the 
International Classification of Functioning, Disability and Health (ICF)[10]. This 
report did not cover the activity and participation levels of this classification (ie, 
 
 
functioning of a person as a whole and functioning in a social context), which are 
also key to the assessment of functioning. Pompe disease strongly affects 
patients' ability to carry out daily life activities and participation and is 
furthermore associated with fatigue and pain, suggesting that these are indeed 
important parameters to take into account in the evaluation of treatment for this 
disease [11-13]. 
Therefore, the aim of this study is to present the effect of the combined training 
program on pain, fatigue, activity, and participation. To gain insight into the 
extent to which functional measures were related to the direct training goals, we 
also studied the correlations between the different domains of the ICF model. 
  
 
 
METHODS 
PARTICIPANTS 
As described in our recent report [9], patients were recruited at the Center for 
Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, 
Rotterdam, The Netherlands, which is the national referral centre for patients 
with Pompe disease. The study was approved by the Ethical Committee of the 
Erasmus MC University Medical Center. Inclusion criteria were a confirmed 
diagnosis of Pompe disease, age >17 years, receiving ERT for at least 1 year, and 
not dependent on a ventilator and/or walking device. Concurrent relevant medical 
conditions (eg, cancer, cardiovascular diseases) and participation in other exercise 
training programs were exclusion criteria. From January to September 2010, 105 
adult patients with a confirmed diagnosis of Pompe disease were seen in our 
centre. A neurologist (S.C.A.W.) checked the patients for our inclusion and 
exclusion criteria. Twenty-five patients fulfilled the criteria and were asked to 
participate in the study. All patients agreed and signed informed consent. 
INTERVENTION 
All patients were trained under supervision of physiotherapists at carefully 
selected outpatient clinics. To ensure the uniformity of the training program and 
its supervision, all therapists attended a 1-day instruction program at Erasmus MC 
University Medical Center. The training program consisted of 3 supervised training 
sessions per week lasting 60 to 90 minutes, during a 12-week period. The sessions 
consisted of 3 components and were preceded by a warm up of 5 minutes and 
completed by a 5-minute cool down. The first component was endurance training 
on equipment of choice at 60% of patient maximum heart rate. This was followed 
by 7 resistance exercises, with an initial training weight of 70% of 4 repetitions 
 
 
maximum. Patients were trained with 3 sets of 15 to 20 repetitions. The training 
weight was adjusted when a patient was capable of executing an exercise in 3 sets 
with 20 repetitions. The third part consisted of core stability exercises. The first 
training session was supervised by 1 of 2 researchers from Erasmus MC University 
Medical Center (L.E.M.vdB., M.M.F.), who subsequently attended each training 
site every 2 weeks to monitor the proper conduct of the program. 
MEASUREMENTS AND OUTCOME MEASURES 
To assess the effects of the program, each patient visited the Erasmus MC 
University Medical Center at baseline and after 12 and 24 weeks. Fatigue, pain, 
and patients' functioning at the activity and participation level were assessed 
using questionnaires, and the ActiGraph GT3X device was used to measure the 
amount of physical activity. 
FATIGUE 
The severity of fatigue and its impact on an individual's daily functioning were 
assessed using the Fatigue Severity Scale (FSS). The total FSS score is the median 
of the 9 item scores and ranges from 1 (no signs of fatigue) to 7 (most disabling 
fatigue). Scores ≥4 are indicative of fatigue, and scores ≥5 are indicative of severe 
fatigue [11, 14]. We used the validated Dutch translation of the FSS[14]. 
PAIN 
Two items in the questionnaire were dedicated to assessing the presence of 
pain/cramps (Are you suffering from pain or cramps?: yes/no) and their severity 
(How severe is your pain or cramp?: very mild, mild, moderate, severe, very 
severe). 
 
 
ACTIVITY LEVEL 
Functioning at the activity level was further subdivided into motor function and 
the amount of physical activity patients engaged in. Four tests were included. The 
first was the 6-minute walk test (6MWT) [15]. The second was the Quick Motor 
Function Test (QMFT) [16]. The third was the Rasch-built Pompe-specific Activity 
Scale (R-PAct) [17]. This scale covers 18 activities of daily living reported to be the 
most important and limiting activities for patients with Pompe disease, ranging 
from combing hair to running. Response options are as follows: not able; able, but 
with difficulties; and able without difficulties. The R-PAct score is the median item 
score and is translated to a scale from 0 to 100, with higher values representing 
better functioning[17]. Finally, all patients were fitted with an ActiGraph GT3X 
accelerometer to provide objective measures of the amount of physical activity 
they engage in. Patients were instructed to wear the ActiGraph, mounted on an 
elastic belt around the waist, with the unit positioned over one of the hips during 
waking hours. The ActiGraph monitors were set to activity counts in triaxial mode, 
using a 10-second epoch, which were reintegrated to 60 seconds for analyses. 
Nonwear time was assessed using a minimum of 60 minutes of consecutive zero 
counts allowing up to a 2-minute tolerance of nonzero counts. A minimum of 8h/d 
of wear time on at least 3 days was required to be included in analysis [18]. 
HEALTH STATUS 
Patients' health status was assessed using the Medical Outcomes Study 36-Item 
Short-Form Health Survey version 2 [19]. Norm-based scores were calculated for 2 
summary scores: the physical component summary (PCS) and mental component 
summary (MCS) scores [20]. The scores vary between 0 and 100, with higher 
values representing better function [21]. A score of 50 represents the general 
population mean, with an SD of 10. 
 
 
AEROBIC FITNESS, MUSCLE STRENGTH, AND CORE STABILITY 
Three types of test were done to assess functioning at the body function and 
structure level[9]: (1) aerobic fitness was determined by measuring the maximum 
oxygen uptake and maximal workload through an incremental cycling test (cyclo 
ergometer) to exhaustion [22]; (2) muscle strength was measured by handheld 
dynamometry as described previously [2]; and (3) core stability was evaluated 
before and after training by measuring time in balance (s) for each of the 4 core 
stability exercises of the training program[23, 24]. 
STATISTICAL ANALYSIS 
Median differences in the outcomes parameters before and after the intervention 
were compared using the Wilcoxon signed-rank test for paired samples. For the 
comparison of dichotomous outcomes we used the chi-square test. 
To assess the extent to which functional measures were related to the direct 
training goals (ie, aerobic fitness, muscle strength, core stability), we investigated 
the correlations between changes (before vs after training) in the outcome 
measures of different ICF domains with the Spearman correlation coefficient. 
Significance level was set at P<.05. Statistical analyses were performed using SPSS 
version 20 for Windows.     
 
  
 
 
RESULTS 
PATIENT CHARACTERISTICS 
Twenty-three of the 25 patients enrolled in this study completed the training 
program. Two patients withdrew from the study because it was too time 
consuming for them. The median age of the participants was 46 years, and they 
had been treated with ERT for a median of 3 years (table 1). 
Table 1 | Patient characteristics at baseline 
Characteristics Total group (N=23)  
Gender, n male  (%) 
Age (yr), median (range) 
Disease duration (yr), median (range) 
ERT duration (yr) median (range) 
Training sessions (max. 36) 
SF-36, PCS 
SF-36, MCS 
12 (52%) 
46 (20;71) 
16 (6;32)  
3.1 (1.3;6.5) 
32  (24;36) 
40 (24-53) 
56 (25-69) 
 
Abbreviation: SF-36, Medical Outcomes Study 36-Item Short-Form Health Survey. 
 
Table 2 shows the outcome measures at the body structure level as reported by 
van der Berg [25]. 
  
 
 
Table 2|Outcome measures at body function & structure level; reported by vd Berg [25]  
NOTE. Values are mean ± SD or as otherwise indicated. Abbreviations: HHD, hand held 
dynamometry; QMFT, quantitative motor function test, 6 MWT: six minute walk test * For the 
difference before and after training (paired samples t-test) Ɨ Maximum oxygen uptake, 6MWT, and 
QMFT score were not available for 1 patient. ‡ Core stability: sum score of all items= (back bridge+ 
prone bridge+ left side bridge+ right side bridge)/4  
 
EFFECTS OF 12 WEEKS OF TRAINING 
Fatigue decreased from a median FSS score of 5.33 before training to 4.78 after 12 
weeks of training (P=.001) (table 3). Before training, 77% of the patients were 
fatigued (FSS score ≥4), and 59% were severely fatigued (FSS score ≥5). After 
completing the training program 74% (17/23) of the patients were fatigued, and 
44% (10/23) were severely fatigued.  
  
 Before 
training 
After 
training 
p-
value* 
Aerobic fitness (maximum oxygen uptake; % of 
normative)  (n=22) 
69 ± 17 76 ± 18.0 <0.01 
Muscle strength (HHD sum score of all muscles % 
of normative)  
87.3 ± 7.3 88.6 ± 7.6 0.01 
Core stability (average of all items ‡) (s) 15 (0.0-96.2) 29 (0.0-
88.3) 
<0.01 
6MWT (m) (n=22) 492 ± 89 508 ± 97 0.01 
Muscle function (total score QMFT) (n=22) 51 ± 8.1 51 ± 8.5 0.65 
 
 
Table 3 | Changes in Fatigue, pain, activity and participation  
Outcome measure Before training After training P * 
Fatigue (FSS score) 5.3 (2.11;6.56) 4.8 (1.78;6.67) 0.01 
Pain, number (%)  13/23 (56.5%) 5/23 (21.7%) 0.04 
Motor function (R-Pact score) 70 (54;100) 70 (48;89) 0.49 
Volume of physical activity (Actigraphx 103 
in counts; n=16) 
484,7 (163,4; 
709,8) 
418,3 (151,2; 
905,3) 
0.21 
Qol (SF-36, PCS score) 40 (24;53) 42 (21;51) 0.86 
Qol (SF-36, MCS score) 56 (25;69) 59 (34;69) 0.06 
NOTE. Values are medians (ranges) or as otherwise indicated. Abbreviations: QOL, quality of Life; SF-
36, Medical Outcomes Study 36-Item Short-Form Health Survey. *For the difference before and 
after training (χ2 test for proportions and Wilcoxon signed-rank test for continuous data). 
 
The number of patients reporting pain also decreased after training (13/23 vs 
5/23; P=.04). Before training, 7 patients reported moderate pain, and 6 reported 
mild pain. After training, 5 patients reported mild pain, and none reported 
moderate pain. 
No significant differences were observed in self-reported motor function, as 
measured by the R-PAct. The amount of physical activity, measured as the mean 
number of counts per day using the ActiGraph device, did not change at the group 
level (table 3); 9 patients showed a decrease, and the remaining 7 patients 
showed an increase. 
Median scores and ranges for the PCS and MCS scores are also shown in table 3. 
The MCS showed a borderline significant change from 56.1 to 59.1 (P=.06). 
 
 
CORRELATIONS BETWEEN OUTCOME MEASURES 
Table 4 displays the correlations between changes in the trained parameters 
(aerobic fitness, muscle strength, core stability) at the body structure level and 
the parameters at the remaining levels of the ICF model. Improvements in pain 
and fatigue were not correlated to changes in any of the trained outcome 
measures. 
The improved distance walked on the 6MWT significantly correlated with 
improvements in both aerobic fitness (r=.495; P=.02) and muscle strength (r=.448; 
P=.04); the QMFT showed a borderline significant correlation with aerobic fitness 
(r=.414; P=.06). 
At participation level, changes in the MCS were correlated with improvements of 
aerobic fitness (r=.657; P<.001) and muscle strength (r=.517; P=.01). No other 
significant correlations were found. Improvements in core stability were not 
associated with any of the outcomes. 
  
 
 
 
Table 4 | Correlations between changes in different outcome measures  
Abbreviations: 6 MWT, 6 minute walk test; AG, Actigraph; FSS, fatigue severity score; HHD, 
hand-held dynamometry; MCS, mental component summary; PCS, physical component 
summary; QMFT, quick motor function test; QoL, Quality of Life; R-Pact, Rasch-built 
Pompe-specific Activity scale; VO2max, Maximum oxygen uptake                                
*P<0.05, 
Ɨ
P<0.01 
 
  
 
 
Body level 
(van den 
Berg[25]) 
Fatigue Pain Activity level Participation 
level 
 FSS Yes/ 
No 
Motor Function Amount of 
Physical 
Activity  
QoL (SF-36) 
  6MWT QMFT R-Pact  AG PCS MCS 
Aerobic 
fitness 
(VO2max) 
-.149 .325 .495* .414 -.120 -.120 -.173 .657Ɨ 
Muscle 
strength 
(HHD) 
-.021 .286 .448* .310 .005 .005 -.282 .517* 
Core stability .060 -.161 .245 -.072 .209 .271 -.042 .31 
 
 
DISCUSSION 
We previously showed our combined training program to improve aerobic fitness, 
muscle strength, core stability, and distance walked in a group of mildly affected 
adults with Pompe disease[25]. This study adds that such a comprehensive 
exercise intervention program also has a positive effect on fatigue and pain scores 
and may improve mental health. Our training program did not affect the quality of 
motor function or the amount of physical activity. To gain insight into the extent 
to which functional measures were related to the direct training goals, we also 
studied the correlations between the different domains of the ICF model. Changes 
in fatigue and pain were not associated with improvements in aerobic fitness and 
muscle strength. 
Fatigue is an important feature of late-onset Pompe disease and has been 
reported as one of the disease's most disabling symptoms [11]. Our training 
program significantly decreased the level of fatigue by 0.5 points (FSS score, 5.33 
to 4.78; P=.001). Although the clinical relevance of this change can be discussed, 
we feel that this change of almost 10% is clinically important. It has to be realized 
that this is the average change and that the proportion of severely fatigued 
patients dropped by 15 percentage points. Similar to the study of Gungor et al. 
[12] we found no correlations between reductions in fatigue and improvements in 
muscle strength or in the other trained parameters. Therefore, this finding does 
not support our assumed chain of subsequent effects, with exercise leading to 
improved exercise capacity, which in turn lowers physical load in daily life, 
resulting in less fatigue. Training may therefore affect fatigue through another 
route. For example, it has been suggested that exercise positively influences the 
neuroendocrine system and levels of neurotransmitters,[26] which may influence 
both peripheral and central fatigue. 
 
 
Pain is another complaint frequently reported by patients with Pompe disease 
and impacts on their well-being and quality of life[13, 27, 28]. Our training 
program positively affected pain, reducing the proportion of patients experiencing 
pain from 57% at baseline to 22% after training. Pain in Pompe disease may have 
various causes, including short-term peak loading of weakened or atrophied 
muscles and more long-term mechanical stress. Irrespective of the explanation, 
the pain reduction itself is important for patients with Pompe disease. 
Although the distance walked improved after training, the program did not 
improve the other motor function parameters, either self-reported (R-PAct and 
PCS) or clinically observed (QMFT) [25]. Training thus seems to have a positive 
effect on the speed of movement, but not on the quality of motor function (ie, 
how these activities are performed). It is unlikely that an improvement in speed 
without improvement in how these movements are executed is clinically useful 
for patients. It is nevertheless also possible that the period of 12 weeks is too 
short to achieve changes in the quality of motor function. Finally, task-specific 
training complementary to exercise therapy, shown to have added value in post 
stroke patients [29, 30] may help to improve this. 
The observed correlation between the improved walking distance on the 6MWT 
with both endurance and muscle strength can be explained by the 6MWT being a 
combined assessment of cardiac, respiratory, circulatory, and muscular capacity 
[31]. 
Little information is available about the amount of physical activity of patients 
with Pompe disease (ie, how active these patients are in daily life). Prior to 
training, we found that the level of physical activity, expressed in mean number of 
counts per day, was considerably lower (203.4 × 102) than in healthy controls 
(269.7 × 102) and comparable with the level observed in mildly affected patients 
 
 
with multiple sclerosis (204.7 × 102) [32].This outcome did not improve with 
training. In addition to the reasons previously mentioned, it reflects habitual 
behaviour that may be difficult to change. On the other hand, the improvement 
observed in a subset of patients (all scoring is better on the outcome measures 
compared with the other patients at baseline) may suggest that a relatively high 
level of functioning is required to achieve an effect on this outcome measure. 
STUDY LIMITATIONS 
Our study is the first to focus on the effects of training in patients with Pompe 
disease on a wider range of parameters, including activity and participation. The 
observed changes were relatively small in our study. This might be the result of 
the short training period or the training having a limited effect only. At what point 
a difference becomes clinically meaningful (minimal clinically meaningful 
difference) has not been determined for the measures we used in this study, 
except for the Medical Outcomes Study 36-Item Short-Form Health Survey, and 
the observed effects should be interpreted with caution. 
Our study design does not allow us to exclude the possibility that other factors 
may have played a role in the observed effect. Originally, the study was set up as a 
crossover trial, but all of the patients who started training at the beginning of the 
study continued to do so after the crossover point, and it was decided to analyse 
this as a pre-post study [25]. The original design did allow us to exclude that the 
improvements in strength and endurance were the result of ERT[25]. 
Because of the small sample size and explorative character of the study, we did 
not adjust for multiple comparisons (for testing a number of outcome measures). 
Results are therefore indicative rather than hard conclusions. 
 
 
Other points of concern are the relatively short duration of the study and the 
small number of patients. Longer training and follow-up is needed to confirm if 
continued exercise is required to maintain the effects of training and to see if 
patients can continue training independently outside of the program. 
CONCLUSIONS 
This study suggests that our combined training program, which aimed to increase 
aerobic fitness, muscle strength, and core stability also leads to improvements in 
fatigue and pain and may improve mental health in patients mildly affected with 
Pompe disease. The observed improvements in pain and fatigue were not 
determined by aerobic fitness, muscle strength, or core stability. Further research 
is needed to understand the functional consequences of Pompe disease and the 
underlying mechanisms of exercise. 
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ABSTRACT 
 
 BACKGROUND  
The loss of the ability to walk is among the most prominent signs of Pompe 
disease. The associations with muscle strength have not been described. 
 
OBJECTIVE  
The objective of this study was to estimate the associations of walking 
performance with muscle strength in four specific lower extremity muscle groups 
along with other factors in adult patients with Pompe disease.  
 
DESIGN  
This was a single-center cross-sectional study. 
 
METHODS  
Muscle strength (hand-held dynamometry of hip flexion and abduction and knee 
extension– and flexion) and walking performance (unable, able with aids, 
waddling gait, normal gait) were assessed in 107 patients at their first visit. 
Relationships between walking performance and muscle strength were studied by 
multivariate analyses and regression modelling. Age, gender, body mass index 
(BMI), disease duration, and use of ventilator support were taken into account as 
potential confounders. We transformed the results into a nomogram to allow the 
probability of a patient having a certain level of walking performance to be 
calculated based on the values of the independent variables. 
RESULTS  
 
 
Walking performance declined significantly with decreasing muscle strength of hip 
flexion and abduction and knee extension– and flexion. The final selected model, 
including strength of the hip abductor and knee extensor, BMI, age, gender, and 
use of ventilation, predicted 66% of the cases accurately.   
 
LIMITATIONS  
These results are based on cross-sectional data and do not predict future changes.  
 
CONCLUSIONS  
In adult patients with Pompe disease, walking performance can be explained by 
muscle strength, BMI, age, gender, and ventilation use. Our model gives insight 
into how a patient is expected to walk based on his or her risk factors and serves 
as a starting point to unravelling factors associated with walking performance, 
and ultimately to developing a prognostic model.  
 
 
INTRODUCTION  
Pompe disease is a rare inheritable metabolic myopathy. It is caused by deficiency 
of the lysosomal enzyme acid α-glucosidase which is needed to breakdown 
glycogen in the lysosomes. As a result, glycogen accumulates in several tissues, 
especially muscle cells. The disease presents as a broad clinical spectrum, with 
variable organ involvement, age of onset and severity. The most severe form, 
seen in infants, results in death within the first year of life, while the disease 
progresses more slowly in children and adults [1].  
 
In adults, Pompe disease is characterized by limb-girdle weakness and weakness 
of respiratory muscles (including the diaphragm). Patients develop Duchenne or 
Trendelenburg signs or a swayback posture. Eventually patients lose the ability to 
walk and become wheelchair and/or respirator dependent.  
 
The loss of the ability to walk is one of the most prominent signs and debilitating 
effects of Pompe disease and has been shown to be an important factor in 
determining patients’ quality of life [2]. In general, retaining the ability to walk is 
important to maintain independent from caregivers [3, 4].  
 
Reduced walking performance has shown to be related to decreased skeletal 
muscle strength in several populations, including patients with related 
neuromuscular diseases and elderly [5-9]. However, the associations between 
walking performance and muscle strength have not been described for patients 
with Pompe disease. Results from studies in other neuromuscular diseases cannot 
automatically be generalized to these patients as the distribution of muscle 
weakness, and thus its effects on walking performance, differs [9]. Also other risk 
factors, such as age, BMI and respiratory status that might contribute to a 
 
 
reduced walking performance are not well understood in patients with Pompe 
disease.  
 
By modeling the relationship between walking performance on the one hand, and 
muscle strength and associated risk factors on the other, it will be possible to 
determine a patient’s expected position in the spectrum of walking performance. 
This can give the clinician a better feel for where the patient is in the disease 
process. Importantly, the model can serve as a starting point to further our 
understanding of the factors that determine walking performance in Pompe 
disease, and ultimately to develop a prognostic model for larger patient care 
planning efforts among the integrated rehabilitation team.  
 
The aim of our study was to estimate the associations of walking performance 
with muscle strength of specific lower extremity muscle groups and with other 
factors in adult patients with  Pompe disease.  
 
METHODS 
PARTICIPANTS 
Adult patients with a confirmed diagnosis of Pompe disease were included in this 
study. All patients were first seen between December 2003 and August 2012 at 
the Center for Lysosomal and Metabolic Diseases of the Erasmus MC University 
Medical Center, Rotterdam, the national referral center for patients with Pompe 
disease in the Netherlands. Patients were excluded if they had co-morbidities that 
affected their walking performance.  
On visiting the center, patients were subjected to a standardized set of outcome 
tests, including assessment of muscle strength and motor function tests 
 
 
encompassing the ability to walk. Data from the patients’ first visit to the center 
was analyzed retrospectively. We also recorded age, gender, height, weight, and 
disease duration (time since diagnosis) for each patient. All patients signed 
informed consent. 
 
OUTCOME MEASURES 
Walking performance was classified in four categories (unable to walk, walking 
with aids, walking without aids but with a waddling gait, or walking without aids 
and with a normal gait) according to the item “walking 10 meters” of the Quick 
Motor Function Test (QMFT) [10]. This item was assessed by asking patients to 
walk a 10-m course at their usual pace. Use of aids (canes or walkers) was allowed 
for this test, but patients were challenged to achieve the maximum performance, 
i.e., those who used a wheelchair but could still walk 10 meters were asked to do 
so. Patients were classified as unable to walk when they were fully dependent on 
a wheelchair (i.e. they could not walk more than a few steps without a walking 
aid)). Patients who used a wheelchair but were capable of walking 10 meters were 
scored as “able to walk with aids”. Normal gait was considered as a gait pattern 
without a Trendelenburg or Duchenne sign or swayback.  
 
Skeletal muscle strength exerted during maximal voluntary eccentric contractions 
was measured by hand-held-dynamometry (HHD) (Cytec dynamometer, 
Groningen, the Netherlands a). The following lower proximal muscle groups were 
tested using the break test technique: [11, 12] hip flexors, hip abductors, knee 
flexors and knee extensors. Specifics of the test positions, stabilization and 
dynamometer placement have been described elsewhere [13]. Muscles were 
tested separately for each leg and values were averaged for the two legs. The 
absolute HHD values were used and expressed in Newtons. All measurements 
 
 
were carried out by three physicians specially trained to perform HHD and 
connected to our center.  
 
DATA ANALYSIS  
Median muscle strength values were plotted against the four levels of walking 
performance using box plots. Differences in muscle strength were assessed using 
the Kruskal-Wallis test. When this was significant, the Mann Whitney test was 
used to identify which of the groups differed. Ordered logistic regression was used 
to build a model describing the independent variable walking performance, based 
on the dependent variables: muscle strength of the four lower extremity muscle 
groups, age, gender, body mass index (BMI), disease duration and use of 
ventilator support [3, 14, 15]. A step backward method was used, starting with a 
full model containing all possible independent variables. Variables that did not 
contribute to the model were excluded at a cut-off significance level of 0.20. 
Internal validation of the (full and subsequent) models was assessed using the 
Bootstrap technique with 1000 samples. As measures of predictive ability we use 
the area under the receiver operating characteristic curve (AUC, discriminative 
ability), Nagelkerke’s R2 (goodness of fit), the calibration slope, and the Brier 
Score (predictive accuracy). The most parsimonious model that performed 
satisfactorily in the validation step was reported here. 
Next, based on this model, a nomogram was constructed which allows the chance 
of being in one of the four levels of walking performance to be calculated directly 
from given specific values of the independent variables.  
 
Differences in patient characteristics and muscle strength were tested using SPSS 
for Windows (release 21.0; SPSS, Inc., Chicago, IL). All other statistical analyses 
were performed in R: A Language and Environment for Statistical Computing, 
 
 
version 3.2.2 using the rms package (rms: Regression Modelling Strategies, Frank 
E Harrell Jr, R package version 4.4-1, 2015). Visualization was performed using 
GraphPad Prism (version 5) and the rms package. 
 
RESULTS 
PARTICIPANTS 
During the study period 108 adult patients with Pompe disease were first seen at 
the national referral center and examined. One patient was excluded from the 
analyses because this patient had Pompe disease in combination with spina bifida, 
both interfering with muscle strength.  
Table 1 presents the characteristics of the 107 included patients at their first visit 
to the center. Patients had a median age of 50 years (minimum 25; maximum 76) 
and had experienced symptoms for a median of 15 years. 28% were ventilator 
dependent. In terms of walking performance, 11% were fully dependent on a 
wheelchair, 28% used walking aids, and 43% walked with an abnormal gait 
without aids and the remainder (18%) had a normal walking pattern. None had 
started treatment with ERT at time of examination for this study.  
  
 
 
Table 1| Characteristics of 107 Adult patients with Pompe Disease (First Visit to Referral 
Center) 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASSOCIATION BETWEEN WALKING PERFORMANCE AND LOWER PROXIMAL 
MUSCLE STRENGTH   
 
Figure 1 shows the differences between each of the consecutive walking 
categories in strength of the hip flexors, hip abductors, knee extensors and knee 
flexors. Walking performance declined with decreasing muscle strength. This was 
most obvious for the hip flexors and hip abductors, where muscle strength 
differed significantly between each consecutive level of walking performance (p < 
0.01). For knee extension, no significant difference in strength of the knee 
extensors was found between patients with a waddling gait and those walking 
normally. For strength of knee flexors there were no differences between any of 
the consecutive walking categories. 
Patient Characteristics at First Visit  dy Population (n = 107) 
Gender (male), no (%)  55 (51.4%) 
Age (years), median (minimum-maximum)  
50 (25-76) 
BMI (kg/m2), median (minimum-maximum)  24.1 (15-48)  
Disease duration (years), median (minimum-maximum)  15 (2-48) 
Walking performance, no (%) 
-  Unable to walk  
-  Walking aids 
-  Walking without aids with waddling gait 
-  Normal gait 
  
 12 (11.2%) 
 30 (28%) 
 46 (43%)  
 19 (17.8%) 
Respiratory support at first visit, no (%) 
- No ventilator use 
- Ventilator dependent   
 
77 (72%) 
30 (28%) 
 
 
 
Figure 1 |Relationship between lower extremity muscle strength (expressed in 
Newtons) and walking performance. Unable = fully dependent on a wheelchair; aids = 
walking with walking aids; waddling = waddling gait; normal = normal gait pattern. The P-
value for differences between any of the groups (Kruskal-Wallis test) is shown at the top 
of each graph, while differences between adjacent groups (Mann-Whitney test) are 
indicated by the bridging lines (* = significant differences between adjacent groups).  
 
Table 2 displays the patients’ muscle strength values and other risk factors across 
the four walking categories. Besides reduced muscle strength, patients with more 
impaired walking performance were older, had been symptomatic for longer and 
were more often ventilated compared to those  
 
 
 
Table 2 | Characteristics and Muscle Strength Across the Four Walking Categories a 
 
 Normal 
(n = 19) 
Waddling  
(n = 46) 
Aids 
(n = 30) 
Unable 
(n = 12) 
P value 
Muscle strength (N) 
 - Hip flexion 
 - Hip abduction 
 - Knee extension 
 - Knee flexion 
Characteristics 
 - Age (yrs) 
-  BMI  
 - Disease duration (yrs) 
 - Ventilation (% yes) 
 Gender (% male) 
 
164.5 (99-348) 
163.5 (106-249) 
190.5 (105-246) 
126.8 (45-204) 
 
45.0 (25-72) 
23.1 (19-29) 
1.0 (0-27) 
5.3 
36.8 
 
121.1 (50-308) 
121.8 (40-225) 
176.5 (55-293) 
87.3 (13-220) 
 
46.5 (25-68) 
24.2 (17-48) 
1.5 (0-19) 
15.2 
54.3 
 
91.0 (33-144) 
83.5 (37-175) 
129.1 (35-205) 
73.4 (24-149) 
 
54.0 (26-71) 
25.2 (20-38) 
13.0 (0-30) 
60.0 
43.3 
 
10 (10-93) 
10 (7-65) 
49.0 (3-193) 
52.2 (10-147) 
 
59.0 (33-76) 
23.2 (15-28) 
22.0 (0-32) 
83.3 
83.3 
 
<.001b 
<.001 b 
<.001 b 
.006 b 
 
<.001 b 
.074 
<.001 b 
<.001 b 
.059 
aContinuous variables are shown as median and ranges (minimum-maximum) and compared with the Kruskal-Wallis test. 
Categorical values are expressed as percentages and p-values calculated with Chi square analysis.  
bsignificant differences between one or more of the walking categories 
  
 
 
with normal / less impaired walking performance. Also higher BMI and male 
gender seemed to be more frequent in the more impaired patients. 
 
Stepwise backward elimination of the variables in Table 2 (P < 0.20) 
resulted in an ordered logistic regression model containing the variables 
strength of the hip abductors and knee extensors, gender, age, ventilation 
use and BMI. This was the most parsimonious model and also performed 
well on internal validation (AUC for discriminative ability: 0.76; Nagelkerke’s 
R2 for goodness of fit: 0.66; calibration slope: 0.86; Brier score for 
predictive accuracy (lower is better): 0.14). Higher strength of the hip 
abductors (OR:1.042; CI [1.026-1.057]) and knee extensors (OR:1.011; CI 
[1.001-1.022]), lower age (OR:0.968; CI [0.931-1.005]), lower BMI 
(OR:0.837; CI [0.753-0.930]), female gender (OR:0.365; CI [0.137-0.972]) 
and not using ventilator assistance (OR:4.540 CI [1.379-14.950]) are 
associated with the probability of being in a better walking category. The 
eAppendix provides the regression and validation results for the different 
models that were generated, as well as further information on the 
interpretation of the validation coefficients. 
Figure 2A shows the results of this model transformed into a nomogram. 
This visualization of the model allows the probability of being in one of the 
four categories of walking performance to be calculated directly based on 
given values of the independent variables. The range of each independent 
variable is related to a corresponding number of points on a linear scale. 
The sum of the corresponding points for each variable (total points) 
corresponds with the probability for being in each of the four walking 
categories. Two example calculations, based on two of our patients, both 
with an observed waddling gait, are shown in Figure 2B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2A | nomogram for predicting the change of being at one of the four categories of walking performance in patients with 
Pompe disease   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2B |The probability of being in one of the four categories of walking performance 
can be calculated from the nomogram as follows. First, for each independent variable, the 
value is projected upwards onto the ‘Points’ scale to give the corresponding points. Next, 
these points are added and the total points are projected downwards from the ‘Total 
points’ scale to the scales giving the corresponding probabilities for being in one of the 
four walking categories.  
For example, case report I is a 42-year-old woman with a hip abduction (HA) strength of 
128 Newtons and knee extension (KE) of 147 Newtons who does not use a ventilator and 
has a BMI of 22 kg/m2. In the first step, we project these values onto the top ‘Points’ 
scale, counting 12 points for age, 9 for being female, 49 for HA strength, 14 for KE 
strength, 14 for being ventilator independent, and 45 for BMI. The total points value is 
143. When drawing a vertical line downward, this gives a 70% chance of walking with a 
waddling gait, 25% chance of a normal gait, and <5% chance of other options.  
  
 
 
DISCUSSION  
 
In adult patients with Pompe disease walking performance declines with 
decreasing strength of the lower extremities. This study shows that a patient’s 
probability to have a certain level of walking performance can be calculated based 
on muscle strength and a number of other risk factors. The model we describe 
here enables clinicians to compare a patient’s actual walking performance to that 
expected based on his risk factors, and thereby counsel patients on their current 
disease status and possible supportive measures. It should be further expanded to 
encompass other factors and ultimately develop a prognostic model.  
  
Walking performance declined most obviously with decreasing strength of the hip 
flexion and abduction. The strength of knee extension varied significantly 
between three of the four walking categories only, while knee flexion didn’t 
distinguish between any of the four consecutive categories. This is consistent with 
findings based on muscle-driven simulation which showed that gait was most 
affected by weakness of hip abductors and hip flexors, as well as plantar flexors 
which are not usually affected in adult patients with Pompe disease [16]. 
Observed muscle strength values overlapped considerably between the 
consecutive walking categories, indicating that other patient characteristics, e.g. 
gender and BMI, may affect walking performance also [14, 15, 17]. Concerted 
contraction of muscle groups as a compensation for weakness may play a role as 
well [16]. To compensate for weak quadriceps muscles a hip extensor might be 
included for knee extensor strategy, i.e. using the two joint characteristics of the 
hamstring muscle to move the knee towards extension [18]. Therefore, we 
developed a multivariate regression model to describe walking performance. 
 
 
 
The probability of being in one of the walking categories can be calculated best 
based on strength of the hip abduction and knee extension, age, gender, BMI and 
respiratory support. From the four lower extremity muscle strength groups, only 
hip abduction and knee extension contributed to the final model because of the 
interdependence between the four groups. Despite disease duration being 
associated with disease severity [19], this variable didn’t contribute to the model 
after correcting for age. In our model women had a higher chance of being in a 
better walking category. These gender differences were also found by De Vries et 
al. [20].   
 
One of the perspectives of creating a multi-variate model is the application in 
clinical practice, and therefore the model was transformed into a nomogram. By 
doing this, a patient’s chance to have a certain level of walking performance can 
be calculated based on his risk factors. While a patient’s actual walking 
performance can be observed, the nomogram allows a clinician to compare this to 
the probability of being in the four walking performance categories based on the 
patient’s muscle strength and risk factors. This comparison has several potential 
clinical benefits.  For example, in case that the expected (i.e. the walking category 
with the highest probability) and observed walking performance are the same, 
there are two options: 1) the probability of the expected walking category might 
be the clearly highest, or 2) the probability of the expected walking category is 
quite close to the probability of an adjacent walking category. In the first 
condition, a patient can be reassured and has not to be prepared on a change to 
another walking category. In the second condition, a patient can be advised to do 
strength training and/ or lose weight in order to prolong this particular ambulant 
status. In case of a discrepancy between observed and expected walking 
performance, this might draw the attention to the issues of overload (when the 
 
 
observed walking category is “higher” than the expected one) or underload (in 
case of a “lower” walking category than calculated).  
 
In the current sample, our model predicted walking performance accurately in 
66% of the cases. Hence, in around 34% of the cases the observed walking 
performance deviated from the model results. Other explanatory factors may play 
a role as well. For example, one of our patients had a high chance of walking with 
aids (70% chance), but was observed to walk with a waddling gait (i.e. 
overloading). Further inspection showed us that this patient had a substantial 
scapula alata preventing the use of a walking stick. This comes at the price of a 
high fall risk and alternative solutions to walking aids need to be searched for or a 
wheelchair recommended. This example illustrates that further factors may need 
to be incorporated to accurately predict walking performance in a prognostic 
model. In future research, it will be important to include instrumented gait 
analysis in order to identify compensatory movements for core and/ or lower 
extremity muscle weakness.  
Our analyses are based on a cohort of more than 100 adult Pompe patients, which 
is very large given the rarity of the disease. However, to develop an accurate 
model patient numbers are relatively small. Nevertheless, internal validation of 
the model yielded a reasonable concordance between actual and estimated 
walking performance, and our model predicted walking performance accurately in 
66% of the cases. A lack of external validation can be regarded as a limitation of 
our study. The model’s validity in other cohorts of Pompe patients remains to be 
studied. Furthermore, the nomogram was based on cross-sectional data rather 
than longitudinal data, and as a consequence it does not provide information on a 
patient’s prognosis or future walking performance. Another limitation is related to 
the measurement of muscle strength. HHD values were obtained using standard 
testing as described and widely used [13]. Three testers (male and female) were 
 
 
involved in this study, where one performed the majority of the strength tests. 
The inter-rater reliability was not assessed, and whether this impacts the clinically 
utility of the nomogram remains to be determined. Finally, in Pompe disease 
trunk muscles are frequently involved [15] which affect strength and performance 
of the lower extremities [21]. Due to the lack of objective measurements of the 
core strength [21] this could not be included in our model. Although plantar 
flexors are known to be important for gait performance we did not included these 
in our model. This was because they are known not to be severely affected in 
Pompe disease, which was supported by the data of our population, with all 
patients having values close to those seen in healthy people[13], which means 
that this would not add to the model. 
This study shows that reduced walking performance in adult patients with Pompe 
disease is associated with reduced muscle strength of the lower extremities, as 
well as with higher age, higher BMI, being male and using a ventilator. We 
developed a model describing the chance to be in one of four walking categories. 
This model can support a clinician’s subjective judgement on whether a patient - 
based on his risk factors- is capable of more or less than what a patient shows in 
terms of walking performance. Moreover, it might serve as a first step towards 
developing a prognostic model.  
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CHAPTER 7 
 
 
General discussion  
 
  
 
 
DISCUSSION  
With the introduction of enzyme replacement therapy in 2006, Pompe disease 
became the first neuromuscular disorder for which a disease-specific treatment is 
available. This changed the perspectives of patients with Pompe disease for the 
better. With these changed perspectives the call for additional forms of therapy, 
such as physiotherapy, became stronger.  
The overall aim of this thesis was to describe the role of the physiotherapy in the 
field of Pompe disease and to investigate whether physiotherapeutic care of 
patients with Pompe disease is a valuable addition to the existing enzyme 
replacement therapy. For this we identified specific sub-aims:   
1. to gain insight into the existing generic physiotherapeutic care in Pompe;  
2. to explore the feasibility and effectiveness of a training intervention;   
3. to gain insight into the extent to which walking performance can be 
explained by muscle strength and other mediating factors with the aim of 
building a model;  
4. to determine the prevalence of incontinence in the Dutch Pompe 
population and to explore the application of pelvic floor physiotherapy. 
This chapter discusses the main findings of our studies and their significance for 
clinical practice. Besides it describes the role of the physiotherapist in Pompe 
disease in specialised centres, including physiotherapeutic testing, and it also 
provides perspectives for the future.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
MAIN CONCLUSIONS OF THIS THESIS 
• There is a lack of guidance for physiotherapeutic care of patients with 
Pompe disease and a strong need for it (chapter 2) 
• Reduced muscle strength of the lower extremities, higher BMI, male 
gender, use of respiratory support and older age increase the risk for 
decreased walking performance (Chapter 5).  
• A combined training program, consisting of aerobic, strength and 
core stability training appears to be safe and improves endurance, 
core balance, muscle strength and muscle function, and reduces 
fatigue and pain (Chapter 3 & 4).  
• One in two adult patients with Pompe disease have incontinence.  
• Both regular and pelvic floor physiotherapeutic care of patients with 
Pompe disease in the Netherlands is scattered and diverse (chapter 2 
& 6). 
• When offered pelvic floor physiotherapy for incontinence, 41% chose 
to be referred, of which 75% benefited. (Chapter 6) 
 
 
 
MAIN FINDINGS  
PHYSIOTHERAPEUTIC CARE OF PATIENTS WITH POMPE DISEASE IN THE 
NETHERLANDS  
PHYSIOTHERAPY IN THE FIRST LINE  
Before the introduction of enzyme replacement therapy (ERT) a sedentary 
lifestyle was recommended to patients with Pompe disease to prevent overuse of 
the damaged muscle tissue [1]. This may be one of the reasons, together with the 
rarity of the disease, that little was known about -the effectiveness of- 
physiotherapy in Pompe disease in general and exercise in particular. With the 
success of ERT, perspectives of patients changed and the call for additional forms 
of therapy, such as physiotherapy, became stronger. In order to get an insight into 
current practices in terms of referral, type of treatment, and perceived benefit, 
we performed a survey among 88 Dutch adult Pompe patients and 31 
physiotherapists.  
At the time of this survey (2009) more than half of the patients did not receive 
physiotherapeutic care for symptoms related to Pompe disease and 40% of 
patients had never been treated by a physiotherapist. The most common reason 
for not being seen by a physiotherapist was that patients indicated that they 
perceived no restrictions in daily life. We noticed the same in the study on 
incontinence. When offered a referral to pelvic floor physiotherapy, 59% of the 
patients with reported incontinence did not want to take this up, mainly because 
they stated that they perceived relatively little burden of incontinence. This is 
consistent with a study on care-seeking behaviour in a general population, for 
which 1,067 Dutch people have been questioned on the use of physiotherapy. 
 
 
More than half of the people with physical complaints procrastinated a visit to a 
physiotherapist, or did not visit at all [2]. One of the reasons for this 
procrastination behaviour was denial of physical complaints. Also, a lack of 
knowledge about the referral procedure (in the Netherlands the physiotherapist 
can be accessed directly without a referral) and  treatment possibilities and the 
costs of physiotherapeutic care may play a role [3].  
In our study on existing physiotherapeutic care in Pompe disease, decreased 
muscle strength and loss of general condition were the main reasons for referral 
by medical doctors. These reasons for referral were largely reflected in both 
treatment goals and interventions used, but in 32% of cases a discrepancy was 
observed between treatment goals and reason for referral, and in 47% of cases 
the treatment given did not match the reason for referral. Although there was a 
wide range of treatment interventions, the most commonly used intervention was 
muscle strengthening exercises, often combined with aerobic exercises. However, 
there was a lot of uncertainty about the way the treatment should be designed, in 
particular, about the extent of muscle load-bearing capacity that patients could 
tolerate. This can be partly explained by the rarity of Pompe disease, which gives 
the physiotherapist little chance to develop relevant experience with this disease. 
Also the lack of guidance and research leads to unclearness on the extent of 
capacity that patients can tolerate. The possible added value of physiotherapeutic 
care in patients with Pompe disease could not be evaluated due to the wide range 
of reported treatment interventions and the large variety of outcome measures 
used. To examine the added value of physiotherapy in Pompe disease, there must 
be uniformity with regard to treatment interventions. Both patients and 
physiotherapists indicated in the survey that they had a strong need for clear 
guidelines for physiotherapeutic care in Pompe disease in general and exercise 
therapy in particular. 
 
 
EXERCISE TRAINING IN MILDLY AFFECTED PATIENTS WITH 
POMPE DISEASE 
 
A first step in the development of physiotherapeutic guidelines was the 
elaboration of a standardized and well-structured exercise program. In related 
neuromuscular diseases, exercise training has been reported to beneficial effects 
on both endurance and muscle strength [4-8]. Before ERT became available, one 
study had been conducted on exercise training in patients with Pompe disease [9]. 
Over a mean period of 4,5 years, 26 patients were subjected to a combination of a 
diet and submaximal aerobic exercises, which was reported to lead to a slower 
deterioration of muscle function. After the introduction of ERT, another study 
reported on the positive effect of a 20-week exercise program consisting of 
aerobic and progressive resistance exercises, in combination with ERT in 5 
patients. This small study showed an improvement on both muscle strength and 
walking distance [10]. These preliminary data strengthened our ideas that the 
exercise training program that we had introduced as part of a study could be an 
effective way to increase strength and endurance in adult patients with Pompe 
disease. So far, due to the small numbers of patients and the diverse interventions 
and outcome measures used, firm conclusions about the effectiveness of these 
interventions cannot be drawn.  
Before starting a study on the safety and efficacy of exercise training in 25 
patients we carefully considered which exercises to include. Besides cardio 
exercises, we also chose to train all those muscle groups that are affected by 
Pompe disease, including the core muscles. This led to a three month intervention 
study in which we offered a combined program of aerobic, strength and core 
stability training. The study showed that this combined program was safe and 
 
 
improved endurance, muscle strength and core stability. Our study also showed 
that such a comprehensive exercise intervention program also has a positive 
effect on fatigue and pain scores and may improve mental health. The assumption 
that exercises can cause structural damage to muscle cells with no or less GAA 
activity, thereby aggravating muscle weakness, is not confirmed by our findings. 
Moreover, the results of our study imply that muscles affected by Pompe disease 
are indeed trainable, with regard strength, endurance and proprioception. 
However, we are not certain whether the increased strength resulted from 
strength training, core stability training or from both. Core stability may support 
gains in muscle strength by improving proprioception and coordination. 
CORE STABILITY  
The core region is the area bounded anteriorly by the abdominal muscles, 
posteriorly by the lumbar multifidus, superiorly by the diaphragm, and inferiorly 
by the pelvic floor muscles (PFM) [11].  These muscles are important for stabilizing 
the spine and pelvis, providing proximal stability for distal mobility and function of 
the limbs during everyday activities. It has been theorized that a strong core will 
allow a transfer of forces from the lower extremities to the upper body with a 
minimal dissipation of energy in the trunk. If power is created but not transferred, 
performance (i.e., running, jumping, throwing, etc.) will be negatively affected 
[12]. The sequence of muscle activation during whole body movements was 
examined in two studies and it was found that some of the core stabilizers (i.e., 
mm. Transversus abdominis, Multifidus, Rectus abdominis, and Oblique 
abdominals) were consistently activated before any limb movements [13, 14].  It 
is the mm. Multifidus and the Obliquus Internus Abdominis that are affected first, 
followed by the Transversus and Rectus Abdominis muscles, according to a MRI 
study in 30 patients with Pompe disease [15]. The core stability exercises applied 
 
 
in our training study, in prone, supine and side positions, target these muscle 
groups. Several studies examined core muscle recruitment while performing these 
so-called bridge exercises [16, 17]. Depending on the individual needs of a 
patients some of the exercises may be more beneficial than others to achieve 
strength. However all exercises demonstrate co-activation of muscle groups and 
should therefore be beneficial for stabilization or endurance training [17]. It is 
however not clear whether the change in balance control can be transferred into 
everyday life [18]. Although the distance walked, measured by the 6 MWT, and 
speed of movement, measured by the four step climb, improved after training, 
the program did not improve the other motor function parameters, either self-
reported (R-PAct and PCS) or clinically observed (QMFT). Moreover, we did not 
find significant correlations between core stability and any of the motor function 
parameters. A possible explanation is that the core assessment was an isometric 
muscle endurance test, whereas the motor function tests, as used in this study, 
involved dynamic movement. Okada et al. advocate that the lack of correlation 
between core stability and motor function suggest that core stability alone is not a 
strong predictor of performance [13]. Our combined training program thus seems 
to have a positive effect on the speed of movement, but not on the quality of 
motor function, i.e. how these activities are performed. It is unlikely that an 
improvement in speed without improvement in the way these movements are 
executed is clinically useful for patients. It is nevertheless also possible that the 
period of 12 weeks may be too short to achieve changes in the quality of motor 
function.  
  
 
 
RECOMMENDATIONS FOR MORE SEVERELY AFFECTED PATIENTS WITH POMPE 
DISEASE 
Mildly affected patients respond well to the specific training program, consisting 
of a combination of strength, endurance and core stability exercises. Patients 
followed this training program for three times a week. Although the compliance 
was high, due to supervision and weekly telephone consultations, a training 
frequency of three times a week is rather time consuming. Moreover, too many 
exercises may not be feasible for patients due to commonly reported exercise 
barriers such as lack of time and fatigue [19]. All patients, except two, continued 
this training program two times a week after the  end of the study. This reflects 
the beneficial effects these patients experienced. These positive experiences 
make it worthwhile to adapt the program for more severely affected patients. 
Adaptations involve modifications in length or intensity of each of the different 
parts of the program and/or modifications of the equipment. Arm crank 
ergometers and wheelchair ergometers are the instruments most commonly used 
to train endurance of wheelchair-dependent patients. For the core stability 
training a Swiss ball or balance cushion can be used. When the minimum weight 
of the traditional fitness equipment is still too high to train the patients, elastic 
straps, can be used to perform each exercise from our study. We have developed 
a folder containing all these exercises. Finally, if some of the exercises from our 
initially training study are too strenuous, they can be replaced by exercises that 
target the muscle groups that are still trainable and are important for performing 
daily activities independently, such as eating and drinking or personal hygiene.  
If rehabilitation goals remain limited to improve outcomes on body structure & 
function level of the ICF model (see figure 1, page 17, general introduction), this 
will reduce the ability of helping patients to improve activities from daily life. The 
results of our training study therefore support specificity of training. Task-specific 
 
 
training complementary to exercise therapy have shown to have added value in 
post stroke patients [20]. Task-specific strength training combines both the 
concepts of strength training and task-specific training. Strength training can be 
defined as the progressive increase in resistance to a muscle or movement during 
training to induce greater ability to produce and sustain force. Task-specific 
training can be defined as motor learning enhancing specificity of training by 
involving practice of activities that are specific to the intended activity [21].   
WALKING PERFORMANCE  
Walking, climbing stairs, lifting and bending are every day functional activities that 
are frequently limited in patients with Pompe disease. Hagemans et al. reported 
that 87% of patients with Pompe disease who were not receiving ERT, 
experienced problems with walking, varying from imbalance or a waddling gait to 
a complete inability to walk [22]. The loss of the ability to walk is one of the most 
prominent signs and debilitating effects of the disease and has been shown to be 
an important factor in determining patients’ quality of life. In general, retaining 
the ability to walk is important to maintain independent from caregivers [23-25].  
The relation between muscle strength and walking has been well established in 
healthy individuals and also in (related) neuromuscular disorders [26-28]. 
However, for Pompe disease this relation was not clear yet. Understanding 
relative contributions of lower extremity muscle strength to walking performance 
might help to tailor physiotherapeutic interventions. As strength training is one of 
the three pillars of our exercise protocol for patients with Pompe disease, it 
might, in this light, be important to prioritize strength training targets. Therefore, 
we studied the associations of walking performance with muscle strength in four 
specific lower extremity muscle groups in 107 adult patients with Pompe disease. 
Walking performance declined most obviously with decreasing strength of the hip 
 
 
flexion and abduction. The strength of knee extension only varied significantly 
between walking with aids and unable to walk. Knee flexion did not distinguish 
between any of the four consecutive categories. Of note, the results of this study 
do not suggest that interventions should exclusively target hip abduction and 
flexion, and knee extension. It is also important to consider the complexity and 
timing of muscle activation during walking [29]. Concerted contraction of muscle 
groups as a compensation for weakness may also play a role. In addition, other 
risk factors, both demographic and disease specific characteristics, might 
contribute to a reduced walking performance as well. For that reason we 
developed a multivariate regression model to describe walking performance. 
Besides reduced muscle strength, a higher BMI, older age, male gender and the 
use of a ventilator increased the patient’s risk on the inability to walk. Like 
strength, BMI is a factor modifiable by lifestyle changes and therefore a potential 
target for intervention.  
For clinical use, the regression model was transformed into a nomogram. 
Although a patient’s actual walking performance can be observed, this nomogram 
can be helpful in the physiotherapeutic management of patients with Pompe 
disease. The nomogram allows the visualization of the chances on a particular 
walking category of a patient, which can be used for counselling purposes such as 
discussing the use of (walking) aids, life style changes and exercises. By using the 
nomogram, the discrepancies between performance and capacity can also be 
made transparent; whether a patient—based on risk factors—is capable of more 
or less than what a patient shows in terms of walking performance. Both could 
lead to conditions that are undesirable, whereby intervention by a therapist is 
needed. Underload might be related to a decreased activity level, which could 
result in disuse atrophy. Overload might be associated with a higher risk of falling.   
 
 
The current model is based on cross-sectional data which do not predict future 
changes. To develop a prediction model repeated measurements over time are 
needed. Besides, future studies are needed to verify whether other muscle 
groups, known to be associated with gait performance and/or frequently involved 
in Pompe disease, might be included as well. It is known that weakness of hip 
extensors and core stabilizers also affect the walking performance [12] [29].  
INCONTINENCE IN POMPE DISEASE 
The pattern of muscle weakness in Pompe disease typically fits a pattern of limb-
girdle myopathy, with the core and hip muscles being the most affected muscle 
groups [30-32]. Caudal, the core region is bounded by the pelvic floor (figure 1) 
[11]. Although the pelvic floor muscles (PFM) are part of the limb-girdle region, 
possible involvement of this muscle group and the accompanying consequences 
have remained underexposed in Pompe disease. The PFM are part of the core 
stability mechanism and their function is interdependent with other muscles of 
this system [33]. Pelvic floor muscles contribute to trunk and lower extremity 
movement control by generating and controlling intra-abdominal pressure 
together with other muscles surrounding the abdominal cavity [14, 33, 34]. PFM 
are also likely to be active with respiratory tasks. It is well accepted that PFM 
activity accompanies coughing and resisted expiration [34, 35]. Therewithal, PFM 
also contribute to continence. Continence is achieved when the pressure resulting 
from direct action of the PFM is greater than the pressure exerted on the bladder 
through abdominal Valsalva-forceful attempted exhalation against a closed 
airway, which enhanced the abdominal pressure- or bladder smooth muscle 
contraction [36].  
 
 
 
 
 
 
 
 
 
 
 
Figure 1 | Muscles of the core  
A handful of studies report on the occurrence of incontinence in adult patients 
with Pompe disease, considering  glycogen accumulation in smooth muscle tissue 
of both bladder and bowel as main cause [37-41]. In a general population 
incontinence is related to a dysfunctional closing mechanism of bladder, sphincter 
or PFM. Pathophysiologic hypotheses for incontinence in myopathies, such as 
myotonic dystrophy, include additional striated pelvic floor muscle involvement 
[42]. This is underlined by a MRI study in adults with Pompe disease showing that 
PFM are also affected [15]. The involvement of the muscles of the pelvic floor may 
lead to pelvic floor dysfunction, defined as abnormal function of the pelvic floor 
muscles and structures that depend on its support [43]. Dysfunction of the pelvic 
floor muscle can cause imbalances of the pelvic floor muscles and abdominal 
pressure that result in urinary (UI) and fecal incontinence (FI) [44].  
Over the years, a substantial number of patients indicated that they experienced 
incontinence during daily life activities and reported this at their regular visits to 
our centre. Besides our study, three studies have reported on the prevalence of 
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incontinence in adult patients, albeit using different definitions resulting in a wide 
range of figures [37, 38, 40]. To get a clear picture of the prevalence in our 
population we started asking about incontinence during patients’ regular visits. In 
addition, we offered patients with incontinence a referral to a pelvic floor 
physiotherapist as they are educated in treating pelvic floor dysfunction. 
Although, pelvic floor physiotherapy (PFPT) might be beneficial, it still is an 
unknown treatment option for patients with Pompe disease. Therefore, we 
initiated a study aiming to describe the characteristics of incontinent patients with 
Pompe disease on one hand and to describe the referral to PFPT as a potential 
beneficial treatment option for this population on the other. 
The first results of this study focused on the prevalence of incontinence in the 
Dutch Pompe population and their characteristics. We found a prevalence of 
incontinence in about one in two adult patients. Patients who were longer and 
more severely affected by the disease were more likely to report incontinence 
than those who were shorter and less severely affected. It is striking that, in 
contrast to a general population, there is no association between incontinence 
and age. Consequently, incontinence symptoms can occur at any age, which is in 
line with two studies on incontinence in Pompe disease [38, 40]. Our prevalence 
figures appeared in the same range as compared to the general population in the 
Netherlands. When we initiated this study, we expected a significantly higher 
incidence of incontinence in patients with Pompe compared to the general 
population. However, we distinguish double incontinence (DI) as a separate 
category of incontinence. This means that our prevalence figures for both UI and 
FI were relatively lower, making these data incomparable. When assuming two 
categories UI and FI we find, compared to the general population, a slightly higher 
prevalence for UI in Pompe patients (39.7% versus 36.8%), and a substantial 
higher prevalence FI (23% versus 7.9%), with a preponderance of FI in men as 
 
 
opposed to women. Other studies reporting the prevalence of incontinence in 
adult patients with Pompe do not distinguish either between UI, FI and DI. In 
addition, the use of different definitions and outcome measures make these data 
incomparable. Finally, since incontinence is still a topic which is often associated 
with embarrassment, the anonymous survey make patients admit their problems 
more frequently and honestly [45]. Incontinence is often unreported by patients 
and undetected by physicians, and consequently the actual prevalence may be 
higher[46].  
The second part of this study described the referral to pelvic floor physiotherapy 
(PFPT) and the characteristics and reported outcomes of treatment. In a general 
population PFPT is an evidence based and minimally invasive therapy, and may be 
offered as a first-line treatment choice to patients experiencing pelvic floor 
dysfunction. PFPT was offered to all patients reporting incontinence. However, 
almost two-thirds chose not to be referred. When offering a referral, more than 
half of our patients (59%) did not want to take this up, because they perceived 
relatively little burden of incontinence (60%) in daily life. This is also seen in a 
general population, as incontinence may not be seen as life threatening and 
patients therefore only seek help when the symptoms become disabling or 
bothersome [47]. Also in our survey on general physiotherapeutic practice in the 
Netherlands little symptom burden was the main reason for patients not wanting 
to be referred. It can be questioned whether there is actually little symptom 
burden or that a lack of knowledge among patients about physiotherapeutic care 
in neuromuscular diseases might contribute as well. Nowadays, the majority of 
our Pompe population receives physiotherapeutic care for symptoms related to 
Pompe disease. This is partly due to information about the usefulness of 
physiotherapy, which are based on the results of our training study.  
 
 
Another resemblance between these studies is the diversity of interventions, e.g. 
types of exercise used, quantity, intensity and subjectivity and variability of 
outcome measures used. This is a common problem in evaluating and comparing 
results of physiotherapeutic interventions in neuromuscular diseases [25]. The 
underlying problem is the heterogeneity of the patient population due to the 
difference in the specific progress of the disease and in the severity of the muscle 
involvement, which causes variations in muscle response to exercise. Also patient 
specific characteristics play a role, such as pre-exercise conditioning status and 
motivation to carry out a rehabilitation program. [22].  
Although the majority of the patients who received PFPT perceived it as 
beneficial, it was not possible to assess how this corresponded with changes in 
outcomes such as tone, strength or endurance of the pelvic floor muscles. 
Consequently, there is no consensus regarding the most efficient intervention or 
combination of pelvic floor physiotherapy interventions for Pompe disease. 
Therefore, future studies are needed with a core set of outcome measures and 
standardised interventions. First of all, the pelvic floor muscle function has to be 
investigated. It remains unclear whether there is overactivity, underactivity of the 
pelvic floor muscles or a combination of both, and to what extent. The assessment 
of muscle tone, strength, endurance and coordination is difficult due to uniform 
use of reliable measurement techniques, and absence of cut-off values for 
pathological conditions [36]. Future direction should also be taken to unravel the 
pathophysiology, in order to see to what extent smooth muscles, striated muscles 
and neurological innervation play a role in incontinence in Pompe disease. The 
exact pathophysiological pathways leading to incontinence in Pompe disease are 
still unknown. The most reliable hypothesis suggests that accumulation of 
glycogen in both smooth and striated musculature is causative, and the possible 
involvement of the autonomic nervous system as well. This could allow better 
 
 
tailoring of individual training programmes and would enable more Pompe 
patients with incontinence to benefit from PFPT.  
 
PHYSIOTHERAPY IN SPECIALIZED CENTRES  
All patients in the Netherlands with a confirmed diagnosis of Pompe disease visit 
the Center for Lysosomal and Metabolic Diseases (CLMD), Erasmus MC University 
Medical Center in Rotterdam regularly. This centre is the Dutch national referral 
centre for patients with Pompe disease. Once the diagnosis has been made, 
physiotherapeutic testing plays an important role in monitoring the disease 
progression and estimating the effectiveness of treatment by identifying and 
quantifying muscle involvement and motor and functional impairment.  
MUSCLE STRENGTH TESTING 
Skeletal muscle strength can be measured with either manual muscle testing 
(MMT) or quantitative muscle testing (QMT). The most commonly used method to 
evaluate manual muscle strength is the Medical Research Council Manual Muscle 
Testing scale (MRC). This method involves testing key muscles from the upper and 
lower extremities against gravity and the examiner’s resistance and grading the 
patient’s strength on a 0 to 5 scale [48]. MMT is a quick, simple to perform and an 
inexpensive way to measure the distribution and progression of weakness in 
specific muscle groups and can be performed with acceptable inter-rater 
reliability by trained health care providers in any setting [49]. However, the 
outcome is subjective, and the scaling does not meet the requirements of an 
interval scale, where grade ‘4’ may encompass a span of weakness so large that 
clinically relevant details are lost [50, 51].  
 
 
QMT involves the use of hand-held or fixed dynamometers. Dynamometry and 
fixed (computerized) QMT involve maximum voluntary isometric contraction 
against an electronic force transducer or strain gauge [52]. Both types of muscle 
tests provide quantitative data on a continuous scale and show fair to good 
reliability. The choice between the different muscle tests depends on both the 
availability of the equipment, training of the examiner and the applicability in the 
patients. A hand-held dynamometer (HHD) and a fixed dynamometer yield 
comparable results in patients with neuromuscular disease. However, the use of 
an HHD depends on stabilization by the tester, creating a potential source of 
tester error, mainly when stronger muscles are being tested (ie, those producing 
forces >250 N) [52]. Compared to a hand-held device, fixed QMT require 
sophisticated equipment which makes it more expensive. Moreover, fixed QMT is 
limited by its applicability.  More severely affected patients experience difficulties 
or limitations in accessing the test couch or chair. The number of muscles that can 
be tested is less and a room with a fixed set-up of the equipment is needed. In 
contrast, HHD can be used at whatever location. A limitation of all muscle tests is 
the lack of a gold standard method for measuring strength of the trunk muscles 
[53].  
Table 1 | Overview of different types of muscle strength testing / different tools for isolated 
muscle strength testing 
 MMT QMT 
 MRC HHD Fixed dynamometry 
    
Objective outcomes: - + + 
- Reliable outcomes, strength <250N N/A + + 
- Reliable outcomes, strength >250N  - + 
- Reproducible outcomes N/A + + 
Easy to perform + + - 
Suitable to all patients + + - 
Applicable for all muscles + + - 
Price devices  N/A + - 
 
 
 
MUSCLE FUNCTION TESTING  
Functional measures are recommended to evaluate the strength, function and 
endurance of the motor system as a whole. These measures assess typical gross 
motor tasks and antigravity functional movements with standardized methods 
including timed functional tests. Functional measures can assist in monitoring 
disease progression and response to treatment. Muscle function can be measured 
using a variety of tests. The 6 minute walk test (6MWT) is a frequently used test in 
the evaluation of walking capacity and provides information on endurance as well 
as walking speed [54]. A downside of this test is that it is not suitable for (partially) 
wheelchair bound patients. Four other timed tests are often used both at regular 
assessments and in trials in Pompe disease, because they reflect aspects relevant 
in daily life: walking 10 metres, climbing four steps, standing up from supine 
position and standing up from a chair. Besides timed tests, which measure the 
speed of movement, also the quantitative motor function test (QMFT), which 
measures the quality of movement, is frequently used. This test specifically 
designed and validated for Pompe patients and consists of 16 specific motor skills 
related to daily activities and to activities that are difficult to execute for patients 
with Pompe disease [55]. All aforementioned functional measures refer to the 
capacity qualifier of the ICF model (see figure 2) which describes the ability to 
execute a motor task or action indicating the highest probable level of 
functioning. It should be noted that these outcomes, measured in a standardized 
environment, may differ from daily practice, which referrers to the performance 
qualifier of the ICF model [56, 57].  
Performance in daily life can be measured using objective tools (accelerometers) 
and subjective (questionnaires) [58]. An accelerometer provides objective 
measures in daily life of the amount of physical activity patients engage in. A 
frequently used tool in Pompe disease to assess motor function in daily life is the 
 
 
Rasch-built Pompe-specific Activity Scale (R-PAct). This questionnaire 
encompasses 18 activities of daily living reported to be the most important and 
limiting activities and social participation throughout the entire disease spectrum 
in patients with Pompe disease [59]. By using the Rotterdam Handicap scale (RHS) 
insight into the social consequences of Pompe disease can be obtained [60, 61]. 
This scale comprises nine inquiries (mobility indoors, mobility outdoors, kitchen 
tasks, domestic tasks indoors, domestic tasks outdoors, leisure activities indoors, 
leisure activities outdoors, ability to drive a car/go by bus/ride a bicycle, and 
ability to work/study) [62].  
 
Figure 2 | ICF levels and subdivision  
  
 
 
RESPIRATORY ASSESSMENTS  
In some experts centres for Pompe disease physiotherapists are involved in 
pulmonary function testing. The most common respiratory symptoms in Pompe 
disease are shortness of breath with exercise and decreased respiratory function 
in supine versus upright positions, both resulting from diaphragmatic muscle 
weakness [63]. Pulmonary function testing involves forced vital capacity (FVC) in 
sitting and supine positions, and maximal inspiratory and expiratory pressure (MIP 
and MEP). As diaphragmatic weakness is common in Pompe disease [64] it is 
important to measure the FVC in both positions. Both mouth pressure 
measurements provide information on respiratory muscle strength [65]. 
Pulmonary testing often encompasses peak cough flow (PCF) and/or voluntary 
cough peak expiratory flow (PEF).  
FATIGUE ASSESSMENT 
Fatigue is a commonly reported problem in Pompe patients [66] and it leads to 
decreased ability to sustain voluntary physical and mental activities. The fatigue 
severity scale (FSS) is a generic nine-item questionnaire that evaluates the severity 
and impact of fatigue [67]. No disease-specific equivalent exists for Pompe 
patients.  
  
 
 
RECOMMENDATIONS 
The systematic use of standardized measures in each category of the ICF model is 
recommended for monitoring disease process over time. Appropriate 
assessments and interpretation of results enable individualized monitoring of the 
disease progress and adjustment of treatment exercise programs to safely 
optimize the patient’s strength, endurance and motor function. In 2014 an 
agreement was reached on a minimal dataset of outcome measures between nine 
European countries, for both data sharing purposes and as a recommendation for 
use in monitoring  patients’ response to treatment [4]. All clinical assessments 
selected were commonly used in the participating countries and deemed to be 
relatively simple to use. With regard to the clinical domains, this dataset covers 
skeletal muscle strength and function and pulmonary function. This set 
encompasses the MRC, 6 MWT, timed tests (ie. walking 10 metres, climbing four 
steps, standing up from supine position and standing up from a chair) and 
pulmonary function tests. Given the benefits of HHD, skeletal muscle strength 
should be added to the MMT, examining muscle groups specially affected in 
Pompe disease.  
Since pain is frequently reported in Pompe disease [60, 68, 69], assessment of 
pain is required at every patient encounter. Pain may be isolated or generalized 
and may be exacerbated by fatigue, overactivity and exercise. As no disease 
specific pain questionnaire is available, the subscale bodily pain of the SF-36 is 
used to evaluate pain in Pompe disease [68, 69] and the use of a generic pain 
assessment tool such as the visual analogue scale (VAS) might be appropriate. 
Besides, the physiotherapist should also exam the possible underlying 
musculoskeletal complaints of the shoulder, hip or low back pain and symptoms 
secondary to Pompe disease, such as restricted range of motion.  
 
 
In addition, given the high prevalence of incontinence of nearly one in two, 
reported in this thesis, clinicians should routinely ask about symptoms of 
incontinence. In order to be able to interpret the severity and implications for 
everyday practice, reliable and valid incontinence questionnaires such as the 
PRAFAB for urine incontinence [70] and Wexner for fecal incontinence should be 
used. 
Finally, with regard to outcome measures, an intermediary role is reserved for 
physiotherapists specialized centres, where many patients with Pompe disease 
are seen. The physiotherapist in a such a centre may identify the need for 
additional physiotherapy treatment and adaptive equipment on the basis of the 
outcome measures used. Results of the described assessments should therefore 
also be used for referral to physiotherapists in the first line. The nomogram, 
described in this thesis, can be used in addition to the clinical assessments in the 
referral to the physiotherapists in the first line. The nomogram can, besides its use 
in monitoring the patient’s response to treatment, also be used for evaluation of 
physiotherapeutic interventions. In this way, the wide variety of outcome 
measures can be reduced, whereby the presumed added value of physiotherapy 
can be evaluated unambiguously.  
RESPIRATORY MUSCLE TRAINING  
Although ERT has positive effects on skeletal muscle function, the effects on lung 
function especially in supine position seem to be less pronounced [71, 72]. In two 
MRI studies on respiratory dysfunction in Pompe disease, severe dysfunction of 
the diaphragm was observed [63, 73]. Dysfunction of the diaphragm and 
weakness of respiratory muscles is considered to play an important role in 
respiratory failure, the main cause of death in Pompe disease. Theoretically, 
respiratory muscles are morphologically skeletal muscles and should respond to 
 
 
repeated training similar to any other locomotor muscles [74]. Therefore, training 
of these muscles might be a treatment option in Pompe disease. Respiratory 
muscle training (RMT), including inspiratory and expiratory muscle training, is a 
well-known and established treatment in patients with chronic obstructive lung 
disease [75], neurodegenerative diseases, like multiple sclerosis and lateral 
amyotrophic sclerosis [76] and several neuromuscular disorders [77] such as 
Duchenne muscular dystrophy [78, 79]. The principle of inspiratory muscle 
training is to improve the strength of the diaphragm and the external intercostal 
muscles [75]. Evidence shows that improvement of inspiratory muscle strength 
might be related to decreased effort in breathing and a positive change in the 
experience of dyspnoea [75]. Little is known about the effect of RMT on 
pulmonary function in patients with Pompe disease. The existing studies on RMT 
in Pompe disease [74, 80, 81] lack comparability due to different training 
programs. Two out of three applied IMT, the other RMT, with varying baseline 
intensity, increase of intensity and length of the training period. All studies 
showed an increased maximum inspiratory pressure (MIP). However, no effect on 
spirometry (e.g. forced vital capacity), motor function tests or patients reported 
outcome measures was observed. This might be due to small sample sizes.  This 
could also be due to the fact that in 2 out of 3 studies only inspiratory muscle 
strength was trained. In many cases it is cough insufficiency (in which expiratory 
muscle strength plays a role) that causes morbidity and mortality in patients with 
neuromuscular diseases [82]. Furthermore, the type of training, in which the main 
aim is to enhance the respiratory muscle strength, might lead to the absence of 
effects on other than muscle strength related outcome measures. A more 
clinically meaningful improvement might be expected when combining it with 
respiratory endurance training [74]. This is something that should be further 
explored in the future. Larger sample randomised controlled trials are needed to 
 
 
determine efficacy of RMT, targeting both strength and endurance, in patients 
with Pompe disease.  
In conclusion, the role of the physiotherapist in the follow-up, treatment and 
guidance of Pompe patients is broad. The studies presented in this thesis were 
instrumental to structure and improve the standardized follow-up and treatment 
programs for patients. We may also conclude that the role of physiotherapist does 
not end here and that there are important challenges ahead of us that may help 
to further improve the prospects and fulfil the unmet needs of patients. 
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SUMMARY   
 
Pompe disease is a rare inheritable metabolic myopathy and lysosomal storage 
disorder. It is caused by deficiency of the lysosomal enzyme acid alpha-
glucosidase, which is needed to break down glycogen in the lysosomes. As a result 
of this deficiency, glycogen accumulates in several tissues, especially muscle.  This 
leads to the loss of muscle strength and function, ultimately leading to wheelchair 
and ventilator dependency.  
In 2006, enzyme replacement therapy (ERT) was registered for all patients with 
Pompe disease, changing patients’ perspectives in terms of improved survival, 
increased muscle strength and walking distance and stabilisation of pulmonary 
function. However, not all patients respond equally well, and not all muscle 
damage and functional impairment can be resolved. Therefore it remains 
important to find additional ways to keep the physical function of these patients 
as good as possible. Physiotherapy aims to maximize the benefits of enzyme 
replacement  and to promote and maintain the maximum level of function, 
functional independence, and participation. However, guidelines for 
physiotherapeutic care are not established for Pompe disease. 
This thesis aimed to investigate whether physiotherapeutic care of patients with 
Pompe disease can be a valuable addition to the existing ERT and how this care 
can be organised. The studies included in this thesis explore the referral patterns 
to contemporary physiotherapeutic care and their content (both regular 
physiotherapy and pelvic floor physiotherapy), the use of exercise training to 
improve patients’ functioning (beyond any improvements obtained from ERT), as 
well as risk factors influencing patients’ walking performance.  
Chapter 1 provides a general introduction to Pompe disease and 
physiotherapeutic care. It provides background information about disease 
pathogenesis, clinical presentation and physiotherapeutic care in neuromuscular 
diseases.  
An overview of the contemporary physiotherapy practice in the Netherlands is 
given in Chapter 2. A survey of 88 adult patients with Pompe disease and 31 PTs 
was performed. Less than 60% of the patients had ever received 
physiotherapeutic care for symptoms related to Pompe disease. At time of the 
survey less than 40% was under treatment of a physiotherapist. Our study showed 
that treatment objectives and interventions were often not in line with the 
referral reason and that the applied treatment interventions were diverse and 
scattered. Nevertheless, the majority of patients and physiotherapists perceived 
physiotherapy as beneficial. It was concluded that there was a great need for 
guidelines for physiotherapeutic care to harmonize the approaches.   
In chapter 3 and 4 we studied the safety, feasibility and added value of exercise 
training in addition to ERT. During 12 weeks 25 patients followed a combined 
exercise program, consisting of aerobic, resistance and core stability exercises 
three times a week.  In chapter 3 we evaluated the effects this exercise program 
on endurance, muscle strength and muscle function and core stability, while 
chapter 4 focussed on pain, fatigue, physical and mental functioning. 23 of the 
patients successfully completed the training. We showed that the training 
program is feasible and was not associated with adverse effects. Furthermore, the 
training helps to improve endurance, muscle strength, muscle function and core 
stability. The training program improved signs of fatigue and pain and tended to 
improve mental health. These results showed that exercise training can be 
performed safely in patients who are mildly affected with Pompe disease, and 
seems to offer added value for these patients. 
The loss of the ability to walk normally is one of the most prominent signs Pompe 
disease, and has been shown to impact greatly on patients’ quality of life. 
Therefore, in the treatment of these patients, the preservation of the remaining 
level of walking performance is of great importance. In chapter 5 we explored 
factors that may influence walking performance in adult patients with Pompe 
disease, with focus on the role of muscle strength of four muscle groups of the 
lower extremity. Based on 107 patients, we found that walking performance could 
be explained by age, gender, BMI, the use of ventilator support and muscle 
strength of hip abductors and knee extensors. Based on this a nomogram was 
built, which can be used by physicians to counsel patients. Ultimately, these 
findings can serve as a starting point to unravel factors associated with walking 
performance and develop a prognostic model.  
In chapter 6 we assessed the prevalence of incontinence in Dutch adult patients 
and described their referral and experiences with pelvic floor physiotherapy. This 
type of physiotherapy might be beneficial to patients with Pompe disease as 
pelvic floor muscles, which are part of the limb-girdle region, might be involved in 
incontinence. During their regular follow up all Dutch patients were asked about 
symptoms of incontinence and were followed if referred to pelvic floor 
physiotherapy. One in two patients reported incontinence. Based on both 
patients’ opinions and patient files from physiotherapists, it seems that pelvic 
floor physiotherapy, aimed at normalizing the tonus of the pelvic floor 
musculature, may be beneficial to these patients. More standardized prospective 
studies are needed to assess this further.  
Chapter 7 discusses the main findings of our studies, our experience with the 
current physiotherapeutic care as well as standardized exercise training and 
contains suggestions for future research.  
SAMENVATTING 
 
De ziekte van Pompe is een zeldzame erfelijke metabole myopathie en lysosomale 
stapelingsziekte. Het wordt veroorzaakt door een tekort aan het lysosomale 
enzym zure alfa-glucosidase, dat nodig is om glycogeen in de lysosomen af te 
breken. Als gevolg van deze tekortkoming stapelt glycogeen in verschillende 
weefsels, vooral in spieren. Dit leidt tot het verlies van spierkracht en 
spierfunctiefunctie en leidt uiteindelijk tot rolstoel- en 
beademingsafhankelijkheid. 
In 2006, is enzymvervangingstherapie (ERT) beschikbaar gekomen voor alle 
patiënten met de ziekte van Pompe, waardoor de perspectieven van patiënten 
zijn veranderd in termen van verbeterde overleving, toegenomen spierkracht en 
loopafstand en stabilisatie van de longfunctie. Niet alle patiënten reageren echter 
even goed, en niet alle spierschade en functionele beperkingen kunnen worden 
opgelost. Daarom blijft het belangrijk om aanvullende manieren te vinden om de 
fysieke functie van deze patiënten zo goed mogelijk te houden. Fysiotherapie 
heeft tot doel de voordelen van enzymvervanging te maximaliseren en het 
maximale niveau van functie, functionele onafhankelijkheid en participatie te 
bevorderen en te handhaven. Er zijn echter geen richtlijnen voor 
fysiotherapeutische zorg voor de ziekte van Pompe.   
Dit proefschrift heeft als doel te onderzoeken of fysiotherapeutische zorg voor 
patiënten met de ziekte van Pompe een waardevolle aanvulling kan zijn op de 
bestaande ERT en hoe deze zorg kan worden georganiseerd. De studies 
opgenomen in dit proefschrift onderzoeken de verwijzingspatronen naar 
hedendaagse fysiotherapeutische zorg en hun inhoud (zowel reguliere 
fysiotherapie als bekkenfysiotherapie), het gebruik van training om het 
functioneren van patiënten te verbeteren (afgezien van eventuele verbeteringen 
verkregen uit ERT), evenals risico's factoren die van invloed zijn op het 
loopvermogen van patiënten. 
Hoofdstuk 1 geeft een algemene inleiding met betrekking tot de ziekte van 
Pompe en fysiotherapeutische zorg. Het biedt achtergrondinformatie over de 
pathogenese, klinische presentatie en fysiotherapeutische zorg bij 
neuromusculaire aandoeningen. 
Een overzicht van de hedendaagse fysiotherapiepraktijk in Nederland wordt 
gegeven in hoofdstuk 2. Een vragenlijstonderzoek werd uitgevoerd onder 88 
volwassen patiënten met de ziekte van Pompe en 31 fysiotherapeuten. Minder 
dan 60% van de patiënten had ooit fysiotherapeutische zorg ontvangen voor 
symptomen die verband houden met de ziekte van Pompe. Op het moment van 
afname van de enquête werd minder dan 40% behandeld door een 
fysiotherapeut. Onze studie toonde aan dat behandelingsdoelen en interventies 
vaak niet in overeenstemming waren met de reden van verwijzing en dat de 
toegepaste behandelingsinterventies uiteenlopend en divers waren. Desondanks, 
gaf de meerderheid van de patiënten en fysiotherapeuten aan  fysiotherapie als 
gunstig te ervaren. Er werd geconcludeerd dat er een grote behoefte is aan 
richtlijnen voor fysiotherapeutische zorg om verwijsredenen, behandeldoelen en 
behandelingen meer op elkaar af te stemmen. 
In hoofdstuk 3 en 4 hebben we de veiligheid, haalbaarheid en toegevoegde 
waarde van training naast de behandeling met ERT bestudeerd. Gedurende 12 
weken volgden 25 patiënten drie keer per week een gecombineerd 
oefenprogramma, bestaande uit duur-, kracht- en rompstabiliteit oefeningen. In 
hoofdstuk 3 hebben we de effecten geëvalueerd van dit oefenprogramma op 
uithoudingsvermogen, spierkracht en -functie en rompstabiliteit. De effecten op 
pijn, vermoeidheid, en op fysiek en mentaal functioneren worden in hoofdstuk 4  
gepresenteerd. De training is door 23 patiënten succesvol afgerond. Met deze 
studie hebben we aangetoond dat het trainingsprogramma haalbaar  en veilig is. 
Bovendien helpt de training het uithoudingsvermogen, de spierkracht, 
spierfunctie en rompstabiliteit te verbeteren. Daarnaast verbeterde het 
trainingsprogramma de tekenen van vermoeidheid en pijn en mentale 
gezondheid. Deze resultaten toonden aan dat deze training veilig kan worden 
uitgevoerd bij mild aangedane patiënten met de ziekte van Pompe en lijkt van 
toegevoegde waarde voor deze patiënten. 
Het verlies van het vermogen om normaal te lopen is een van de meest 
prominente tekenen voor de ziekte van Pompe en er is aangetoond dat dit een 
grote invloed heeft op de kwaliteit van leven van patiënten. Daarom is bij de 
behandeling van deze patiënten het behoud van het resterende niveau van 
loopprestaties van groot belang. In hoofdstuk 5 hebben we factoren onderzocht 
die bij volwassen patiënten met de ziekte van Pompe van invloed kunnen zijn op 
de loopprestatie, met focus op de rol van spierkracht van vier spiergroepen van 
de onderste extremiteit. Op basis van 107 patiënten vonden we dat 
loopprestaties kunnen worden verklaard door leeftijd, geslacht, BMI, het gebruik 
van beademingsapparatuur en de spierkracht van heup abductoren en knie 
extensoren. Op basis hiervan werd een nomogram gebouwd, dat door clinici kan 
worden gebruikt om patiënten te begeleiden. Uiteindelijk kunnen deze 
bevindingen dienen als een startpunt voor het ontwikkelen van een prognostisch 
model.  
In hoofdstuk 6 hebben we de prevalentie van incontinentie bij Nederlandse 
volwassen patiënten met de ziekte van Pompe onderzocht en hun verwijzing en 
ervaringen met bekkenbodemfysiotherapie beschreven. Bekkenbodem 
fysiotherapie kan gunstig zijn voor patiënten met de ziekte van Pompe, omdat 
bekkenbodemspieren, die deel uitmaken van het gebied van de romp, mogelijk 
betrokken zijn bij incontinentie. Tijdens hun reguliere follow-up werden alle 
Nederlandse patiënten ondervraagd over symptomen van incontinentie, waarvan 
één op de twee incontinentie meldde. Alle patiënten die incontinentie 
rapporteerden werden verwezen naar bekkenbodemfysiotherapie en verder 
gevolgd. Op basis van de opgevraagde patiëntendossiers van de behandelende 
bekkenfysiotherapeuten en de mening van de patiënten, lijkt 
bekkenbodemfysiotherapie, gericht op het normaliseren van de tonus van de 
bekkenbodemmusculatuur, gunstig voor deze patiënten. Meer 
gestandaardiseerde prospectieve studies zijn nodig om dit verder te beoordelen. 
Hoofdstuk 7 bespreekt de belangrijkste bevindingen van onze studies, onze 
ervaring met de huidige fysiotherapeutische zorg en gestandaardiseerde training 
en bevat suggesties voor toekomstig onderzoek. 
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zus en schoonouders bedanken. Lieve papa en mama, dank jullie wel voor alle 
kansen die jullie me hebben geboden. Zonder die kansen, jullie liefde en 
vertrouwen had ik hier niet kunnen staan. Lieve Josien, dank je wel voor je 
onvoorwaardelijke support, zowel mentaal als fysiek. Mijn schoonouders, Jan en 
Henriët, bedankt voor jullie liefde, interesse en steun.  
Tot slot, lieve Michel, Philip, Julius en Olivier, het zit er eindelijk op. Op naar 
rustiger vaarwater.  
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